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seen in many acquired and inherited central nervous system (CNS) and peripheral nervous system (PNS)
disorders, such as traumatic brain injury (TBI), spinal cord injury, cerebral ischemia, neurodegenerative
diseases, and demyelinating and hereditary neuropathies. The calpain family of proteases has been causally
linked to many of these acute and chronic disorders. In particular, previous studies have suggested that
pathologic calpain activity may be responsible for axonal dysfunction and degeneration. Even though the
immediate cause of increased intra-axonal calpain activity varies, the downstream effects of calpains may be
similar. To address the role of calpains in axonal injury, I have relied on two animal models: nerve transection
and optic nerve stretch. First, I demonstrated that overexpression of the endogenous calpain inhibitor,
calpastatin, in transgenic mice provided biochemical and morphological protection to transected PNS axons,
and biochemical protection to CNS axons. I then studied the role of calpains in synaptic dysfunction in
transected PNS axons. There was no detectable protection of synaptic function with calpastatin
overexpression. Next, I developed and characterized a new in vivo model of optic nerve stretch that isolates
mechanical strain primarily to axons of retinal ganglion cells in the rat. This model of optic nerve stretch
recapitulates the signature pathology seen in axons after human TBI, which is transport disruption. Within my
study of optic nerve stretch, I used both the pharmacologic calpain inhibitor MDL-28170 and adeno-
associated viral vector-mediated overexpression of calpastatin to examine the role of calpains in impairment of
retrograde transport after mechanical stretch of axons. Calpastatin overexpression, but not short-duration
MDL-28170, protected retrograde axonal transport. Taken together, my dissertation work extends our
understanding of the pathologic role of calpains in axonal injury and degeneration.
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ABSTRACT 
 
ROLE OF CALPAINS IN AXONAL INJURY AND DEGENERATION 
Marek Ma 
Robert W. Neumar 
 
 Axonal injury and degeneration, whether primary or secondary, contribute to the 
morbidity and mortality seen in many acquired and inherited central nervous system 
(CNS) and peripheral nervous system (PNS) disorders, such as traumatic brain injury 
(TBI), spinal cord injury, cerebral ischemia, neurodegenerative diseases, and 
demyelinating and hereditary neuropathies. The calpain family of proteases has been 
causally linked to many of these acute and chronic disorders. In particular, previous 
studies have suggested that pathologic calpain activity may be responsible for axonal 
dysfunction and degeneration. Even though the immediate cause of increased intra-
axonal calpain activity varies, the downstream effects of calpains may be similar. To 
address the role of calpains in axonal injury, I have relied on two animal models: nerve 
transection and optic nerve stretch. First, I demonstrated that overexpression of the 
endogenous calpain inhibitor, calpastatin, in transgenic mice provided biochemical and 
morphological protection to transected PNS axons, and biochemical protection to CNS 
axons. I then studied the role of calpains in synaptic dysfunction in transected PNS 
axons. There was no detectable protection of synaptic function with calpastatin 
overexpression. Next, I developed and characterized a new in vivo model of optic nerve 
stretch that isolates mechanical strain primarily to axons of retinal ganglion cells in the 
rat. This model of optic nerve stretch recapitulates the signature pathology seen in axons 
after human TBI, which is transport disruption. Within my study of optic nerve stretch, I 
used both the pharmacologic calpain inhibitor MDL-28170 and adeno-associated viral 
         vi 
vector-mediated overexpression of calpastatin to examine the role of calpains in 
impairment of retrograde transport after mechanical stretch of axons. Calpastatin 
overexpression, but not short-duration MDL-28170, protected retrograde axonal 
transport. Taken together, my dissertation work extends our understanding of the 
pathologic role of calpains in axonal injury and degeneration. 
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CHAPTER 1: 
 
Introduction: mechanistic roles of calpains in 
axonal injury and degeneration 
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Abstract 
 Axonal injury and degeneration, whether primary or secondary, contribute to the 
morbidity and mortality seen in many acquired and inherited central nervous system 
(CNS) and peripheral nervous system (PNS) disorders, such as traumatic brain injury, 
spinal cord injury, cerebral ischemia, neurodegenerative diseases and demyelinating 
and hereditary neuropathies. The calpain family of proteases has been linked to the 
pathology seen in axons. Even though the direct mechanism by which mechanical strain, 
ischemia or demyelination, may trigger calpain activity may be different, the downstream 
intra-axonal effects of unregulated calpain activity may be similar in these seemingly 
disparate diseases. In this chapter, I briefly review key elements of axonal structure and 
provide a focused overview of the calpain family. Finally, I discuss the mechanisms by 
which calpains may disrupt the axonal cytoskeleton and transport, specialized electrical 
domains (axon initial segment and nodes), and axon terminals. 
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I. Introduction 
 A growing body of work over the past 20 years suggests that the calpain family of 
Ca2+ dependent cysteine proteases is partly responsible for axonal cytoskeletal 
degeneration and axonal dysfunction. In addition to a unique cytoskeleton, axons have 
specialized transport processes as well as electrical and signaling domains, which are 
disrupted in various experimental injury models. Strategies to injure axons, such as 
transection, stretch, and oxygen deprivation, are known to activate intra-axonal calpains. 
In this chapter, I describe the findings from these disparate lines of investigations to 
present a unified understanding of the pathologic roles that calpains plays within the 
axon. 
 
II. Axonal injury and degeneration underlie common neurologic diseases 
A. Traumatic brain injury 
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is 
estimated to afflict over 10 million people annually, and is predicted to surpass many 
diseases as the major cause of death and disability by the year 2020 (Hyder et al., 
2007). There are no approved therapies that specifically targets the molecular cascades 
acutely triggered by TBI. A significant contribution to the morbidity and mortality of TBI is 
from axonal injury (Blumbergs et al., 1995; Povlishock and Becker, 1985; Smith and 
Meaney, 2000). It is estimated that traumatic axonal injury (TAI) accounts for at least 
35% of the morbidity and mortality in blunt TBI patients without space-occupying lesions 
(Büki et al., 2000). In blunt TBI, rotational and shearing forces disproportionately affect 
the long white matter tracts. Axons may stretch on the order of 15 to 30% of their original 
length in susceptible brain regions (Saatman et al., 2003). Except in the most severe 
cases, where axons tear at the moment of trauma, injured axons initially show no overt 
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disconnection but subsequently lose continuity and degenerate (Jafari et al., 1997; 
Maxwell and Graham, 1997; Povlishock and Katz, 2005; Saatman et al., 2003). 
 
B. Spinal cord injury 
 In the United States, there are over 250,000 people living with spinal cord injury 
(SCI; Ray et al., 2011). Like TBI, the victims of SCI are mostly young adults who would 
otherwise be in productive phases of their lives. The only approved therapy for SCI is 
methylprednisolone, but its efficacy is highly controversial (Ray et al., 2011). The 
neurological deficits are predominantly caused by loss of white matter, particularly the 
long tracts through which ascending and descending communications between the brain 
and PNS occur (Medana and Esiri, 2003). Immediately after fatal SCI in humans, a 
proportion of axons was determined to be injured but not transected (Medana and Esiri, 
2003). These injured axons had irregular varicosities, spheroids and ß-APP 
immunoreactivity. ß-amyloid precursor protein (ß-APP) accumulates at sites of 
presumably disrupted axonal transport (Ma et al., 2012). The pathophysiology of SCI is 
extremely complex, and isolating the axonal contribution is challenging in experimental 
models.  
 
C. Cerebral ischemia 
 Cerebral ischemia can be global or focal. Worldwide, the incidence and burden of 
cardiac arrest and stroke are staggering (Berdowski et al., 2010; Bramlett and Dietrich, 
2004; Gustavsson et al., 2011; Kinlay, 2011). In humans, about 50% of the brain volume 
is white matter, which is almost always involved to some degree in stroke (Goldberg and 
Ransom, 2003). Axons often extend for long distances from their somata, and may 
suffer ischemia that do not involve their parent neurons (Medana and Esiri, 2003). Axons 
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are sensitive to ischemia and hypoxia (Pantoni et al., 1996; Underhill and Goldberg, 
2007), and disruption of central conducting pathways may cause significant morbidity in 
patients. 
 
D. Traumatic injury to peripheral nerves  
Traumatic injury to peripheral nerves results in considerable worldwide disability 
(Robinson, 2000). There are three types of traumatic nerve injury: neuropraxia, 
axonotmesis and neurotmesis. Neuropraxia is comparatively mild, with motor and 
sensory loss owing to conduction block but no evidence of axonal degeneration, and has 
an excellent prognosis. Brief ischemia or focal demyelination is the suspected cause. 
Axonotmesis is commonly caused by nerve crush or stretch, where the axon and myelin 
sheath are interrupted but the surrounding basal lamina and collagen remain in 
continuity. Nerve crush or stretch may result in a population of axons that are injured but 
not transected, and therefore potentially salvageable. Nerve transection results in 
neurotmesis, where there is interruption of the continuity of the axon and surrounding 
connective tissue components and basal lamina, and the prognosis is typically poor. 
 
E. Other diseases 
In addition to trauma and ischemia, axonal dysfunction and degeneration are 
important contributors to the morbidity and mortality of many human diseases, such as 
multiple sclerosis and other demyelinating diseases, infections (malaria and HIV), 
neurodegenerative diseases, and peripheral and hereditary neuropathies (Coleman, 
2005; Glass, 2004; Medana and Esiri, 2003; Shaw, 2005; Shy et al., 2002). Thus, 
understanding axon physiology and pathology is critically important to developing 
therapeutic strategies for a broad spectrum of neurological disorders. 
    6 
 
III. Axonal Structure and Function 
 
For the purposes of this chapter, axon regions will be grouped into the following: 
axon initial segment (AIS) and nodal domains, axon proper, and synaptic terminals. 
Action potential is initiated at the AIS, propagated down the axon proper, where it signals 
the release of neurotransmitters at the synapse (see review by Debanne et al., 2011). 
There are two broad types of axons, myelinated and unmyelinated. Myelination is 
accomplished by oligodendrocytes in the CNS and by Schwann cells in the PNS. In 
myelinated axons, action potentials are propagated via saltatory conduction, which 
allows for increased speed of transmission. Ion channels cluster at the AIS and nodes as 
well as in the terminals via ankyrins and spectrins. These specialized domains will be 
described in more detail later. In contrast, unmyelinated axons are generally smaller in 
diameter with more homogenous distribution of ion channels and therefore slower 
conduction. 
The axon cytoskeleton is principally composed of neurofilaments (NF) and 
microtubules. The third type of protein filament, actin, is concentrated in dendritic spines, 
growth cones, and presynaptic terminals. Disruption and disintegration of the 
cytoskeleton are pathologic “signatures” of axonal injury and degeneration. 
Neurofilaments are the most abundant cytoskeletal protein in large myelinated axons 
and are longitudinally oriented and regularly spaced (see review by Perrot et al., 2008). 
They are ~10 nm in diameter and consist of heteropolymers of subunits with molecular 
weights of about 68, 160, and 200 kDa, known respectively as light (NFL), medium 
(NFM), and heavy (NFH) subunits. Each subunit has a central 40 kDA core domain, 
which is used to form coiled-coil structures with other neurofilaments, allowing for self-
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assembly. The two larger isoforms are heavily phosphorylated, mainly in the carboxy-
terminal domain (commonly called the sidearm). Phosphorylation of the sidearms may 
influence inter-neurofilament distance and axonal caliber, an important determinant of 
conduction velocity of action potentials (Perrot et al., 2008). Phosphorylation is 
topographically regulated as heavily phosphorylated neurofilaments are preferentially 
located in axons, while less phosphorylated neurofilament are in the somatodendritic 
regions.  
Microtubules are critically important for anterograde and retrograde transport. 
Disruption of axonal transport is commonly seen after TBI and has been attributed to 
depolymerization or loss of microtubules (Maxwell, 1996; Maxwell and Graham, 1997; 
McCracken et al., 1999; Saatman et al., 2003). Microtubules are hollow cylindrical 
structures with diameters of ~25 nm built from 13 parallel protofilaments, each 
composed of alternating α- and β-tubulin molecules. In the axon, they are oriented with 
their plus ends outward or away from the soma. Their assembly, stability, and 
disassembly are regulated by microtubule-associated proteins (MAPs; Amos and 
Schlieper, 2005). Tau is highly enriched in axons, while MAP1 has a widespread 
neuronal distribution (Bloom et al., 1984; Maccioni and Cambiazo, 1995; Noble et al., 
1989). In contrast, MAP2 is not found in axons in the mature nervous system (Maccioni 
and Cambiazo, 1995).  
 
IV. The Calpain/Calpastatin System 
A. Overview 
Calpains are a family of Ca2+-dependent non-lysosomal proteases involved in 
cytoskeletal remodeling, signal transduction, cell differentiation, embryonic development, 
vesicular trafficking, apoptosis, and necrosis (Zatz and Starling, 2005). Since the 
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discovery of µ-calpain in 1964 (Guroff, 1964), it is now recognized that the human 
genome contains 15 genes that encode calpain-like proteases. Several calpain catalytic 
subunit isoforms (1, 2 3, 5, and 10), two small regulatory subunits, and the endogenous 
inhibitor calpastatin, have been identified in brain. 
The most well-studied calpains are the ubiquitous µ- and m-calpain. These are 
heterodimers that consist of 80 kDa catalytic subunits sharing 50% sequence homology 
(calpain 1 and calpain 2, respectively) and a common 30 kDa regulatory subunit, known 
as (CSS)1 or calpain 4. Consistent with the scientific nomenclature, µ- and m-calpain 
refer to the heterodimers, while calpain 1 and 2 refer to the individual catalytic subunits. 
The major functional difference between µ- and m-calpain is the in vitro Ca2+ 
concentration required for half-maximal activity (the EC50), 3-50 µM and 400-800 µM, 
respectively (Goll et al., 2003). Autoproteolysis of calpain reduces the Ca2+ concentration 
required for its activity. 
Much less is known about the other three catalytic isoforms found in brain. 
Calpain 3, which is a monomeric isoform once thought to be muscle-specific, has a 
domain organization similar to that of calpains 1 and 2. Even though it has been 
detected in neuron-like PC12 cells (Marcilhac et al., 2006), calpain 3 is localized to 
astrocytes, but not neurons, in the rodent and primate brain (König et al., 2003). Calpain 
5 mRNA is present in rat and human brain (Waghray et al., 2004), but the protein has 
not been detected in brain. Calpain 10 protein has been found in rat brain homogenates 
(Ma et al., 2001), and has been localized to mitochondria, where it plays a pathologic 
role in mitochondrial dysfunction via cleavage of Complex 1 subunits and activation of 
mitochondrial permeability transition (Arrington et al., 2006; Kar et al., 2010). µ- and m-
calpains have also been identified in mitochondria. Even though mitochondrial 
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dysfunction may contribute to axonal pathology, the role of calpains in mitochondrial 
dysfunction is beyond the scope of this review. 
Calpastatin is an endogenous inhibitor of both µ- and m-calpain, and is not 
known to inhibit proteases of any other family (Goll et al., 2003). Whether or not 
calpastatin inhibits the other calpain isoforms has not been definitively established. 
There is a single calpastatin gene located on chromosome 5 in humans, but through 
alternative splicing, isoforms ranging in molecular mass from 17.5 to 84 kDa have been 
identified.  
Currently, there are no pharmacologic inhibitors completely specific for calpains 
or individual calpain isoforms (Goll et al., 2003).  The cell-permeable MDL-28170 is one 
of the most well studied calpain inhibitor and ameliorates TAI in global brain injury 
models (Ai et al., 2007; Büki et al., 2003). It does inhibit cathepsin B, although it is 
somewhat more selective for calpains (Ki = 25 and 10 nmol/L for cathepsin B and 
calpain, respectively) (Markgraf et al., 1998). Another commonly used calpain inhibitor, 
ALLN has similar potency for cathepsins B and D and µ- or m-calpains, and has some 
activity against the proteasome  (product data sheet; BioVision Research Products, 
Mountain View, CA). 
Calpains cleave their substrates in a limited manner, often modifying, rather than 
terminating, their function (Sorimachi et al., 2010; Tompa et al., 2004). There is no 
definitive method to predict which substrates are proteolyzed by calpains or to determine 
the calpain cleavage site (Ray, 2006). Even though they have nearly identical 
substrates, µ- and m-calpain have different cellular localization and serve unique 
functions (Honda et al., 2004). Constitutive knockout of calpain 2 or the common small 
regulatory subunit, which is required for stability and activity of both µ- and m-calpain, is 
embryonically lethal (Arthur et al., 2000; Dutt et al., 2006), while calpain 1 knockout mice 
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are viable and fertile (Azam et al., 2001). Depending on experimental model, either µ- or 
m-calpain may contribute to neuronal death. m-calpain promotes death of primary 
hippocampal neurons following NMDA excitoxicity, whereas µ-calpain contributes to 
hippocampal neuronal death after global brain ischemia (Bevers et al., 2009, 2010). 
 
B. Localization of µ- and m-calpains in axons  
All vertebrate cells examined so far have been found to express µ- and m-
calpains (Goll et al., 2003). However, reports describing the subcellular localization of 
calpains 1 and 2 are inconsistent. This is likely due to the relatively poor and variable 
selectivity of antibodies for the two isoforms when used for immunohistochemistry. 
Calpain 1 immunoreactivity was detected in myelinated and unmyelinated axons in brain 
with rare staining of presynaptic terminals (Perlmutter et al., 1990; Siman et al., 1985). In 
contrast, Hamakubo and colleagues (1986) localized calpain 2, but not calpain 1, 
immunoreactivity to CNS myelinated axons. Calpain 2 immunohistochemistry in the PNS 
resulted in staining of rat sciatic nerve axons (Mata et al., 1991). Even though the axonal 
localization of calpains 1 and 2 has not been definitively established, calpain activity has 
been identified throughout the axon and presynaptic compartment (O'Hanlon et al., 
2003; Saatman et al., 2003). 
 
C. Recognition of calpain activity 
In vivo calpain activity can be demonstrated by two methods: measuring 
autoproteolysis and tracking substrate degradation. Autoproteolysis of µ-calpain occurs 
in two stages. For human µ-calpain (80 kDa), 14 amino acids are first removed to 
produce a 78-kDA intermediate product, followed by removal of an additional 12 amino 
acids to produce the 76 kDa fragment (Goll et al., 2003). These forms can be resolved 
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by SDS-PAGE (Hayashi et al., 1991). Autoproteolysis of the 80-kDa subunit of human 
m-calpain reduces the mass to 78 kDa, but this is difficult to resolve by SDS-PAGE and 
therefore is an unreliable measure of m-calpain activation (Goll et al., 2003). The 
cleavage sites are similar but not identical to calpains from other species. 
Autoproteolysis is not required for calpain activity (Goll et al., 2003). 
Substrate proteolysis as a measure of calpain activity can be detected by loss of 
intact proteins or accumulation of lower molecular weight fragments. The most 
commonly used substrate is the 280 kDA αII-spectrin, and its measurement by 
immunoblotting or immunohistochemistry is a sensitive and specific way to assay for in 
vivo calpain activity (Roberts-Lewis et al., 1994). Calpain activity rapidly generates 145- 
and 150-kDA fragments, which lack the ability to self-associate and cross-link actin in 
vitro (Harris and Morrow, 1990). There is an antibody (Ab38) that specifically recognizes 
the C-terminus of the 150-kDA amino-terminal αII-spectrin fragment (Roberts-Lewis et 
al., 1994). 
 
V. Pathologic role of calpains in axons 
 I have decided to focus on calpain substrates that are either preferentially 
localized to distinct axonal domains or that are important to unique axonal functions and 
have been demonstrated to be proteolyzed under pathologic conditions. Calpain 
substrates in the endoplasmic reticulum and mitochondria are reviewed elsewhere (see 
Bevers and Neumar, 2008; Kar et al., 2010), and are beyond the scope of this chapter. 
In addition, calpain substrates like the plasma membrane Ca2+ ATPase (PMCA) or N-
methyl-D-aspartic acid (NMDA) receptors, which are not preferentially localized to the 
axonal or presynaptic compartments, are not discussed here. 
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A. Degeneration of the axon cytoskeleton in Wallerian degeneration 
A.1.  Overview of Wallerian degeneration 
In 1849, Augustus Waller observed that nerve transection results in progressive 
degeneration of the distal portion of the nerve (Waller, 1850). The initial pathology seen 
in this process, now named Wallerian degeneration, is axonal degeneration and the final 
step in the process is myelin clearance (see review by Vargas and Barres, 2007). 
Experimental interruption of axons in vivo is typically done by nerve transection or crush. 
Nerve transection results in neurotmesis, while nerve crush theoretically produces 
axonotmesis. The course of degenerative events is identical between nerve transection 
and crush (Chaudhry et al., 1992). 
It was once believed that when axons are separated from their somata, the 
cessation of anterogradely-delivered trophic factors were responsible for their passive 
degeneration (Vargas and Barres, 2007). However, with the discovery of the Wallerian 
degeneration slow mouse (Wlds), axonal degeneration is now established as an active 
process. The Wlds mutation is an autosomal dominant, spontaneously occurring 
mutation located on mouse chromosome 4. The Wlds gene mutation is an 85-kb tandem 
triplication containing the full coding region of nicotinamide mononucleotide adenyl 
transferase 1 (Nmat-1), the coding region for the N-terminal 70 amino acids of the 
ubiquitination factor E4B (Ube4b), and a unique 18 amino acid linker. The precise 
mechanism by which Wlds mediates axonal protection has not been clearly established, 
but the bulk of the evidence favors a mitochondrial role of Nmnat-1 in preserving axons 
(Coleman and Freeman, 2010).  
After an axon is transected, there is a latency period before axonal degeneration 
is evident. The latency period is typically longer in CNS than in PNS axons but not 
always (George and Griffin, 1994). Transected axons undergo granular disintegration of 
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the cytoplasm (GDC), in which the organelles and cytoskeletal components disintegrate 
(Vargas and Barres, 2007). GDC occurs in some CNS axons and all PNS axons. A 
subpopulation of transected CNS axons undergoes “dark” degeneration, where the 
axons become filled with electron-dense material that obscures visualization of 
cytoskeletal structure (Marques et al., 2003; Narciso et al., 2001). Axons undergoing 
“dark” degeneration are frequently of medium and small caliber, as opposed to larger 
axons that undergo GDC. The functional significance of “dark” degeneration is unknown. 
Transection-induced axonal degeneration in the mammalian CNS and PNS may 
differ by onset and morphology, but ultimately all axon segments distal to the transection 
site degenerate. Currently, the process is irreversible, and delaying this process may not 
be clinically relevant. However, Wallerian degeneration has attracted much scientific 
interest as the underlying molecular mechanisms may be common to many disorders. 
Understanding Wallerian degeneration may reveal better clinical targets for a wide 
spectrum of human diseases. 
 
A.2. Cytoskeletal components are calpain substrates 
Early investigators implicated calpains as causative agents of GDC (Fig. 1; 
(Kamakura et al., 1985; Schlaepfer et al., 1984). All three neurofilament isoforms that 
are degraded during GDC are calpain substrates (James et al., 1998; Kamakura et al., 
1983, 1985; Malik et al., 1987; Schlaepfer et al., 1984, 1985). Of the different 
neurofilament isoforms, NFM appears to be most susceptible to proteolysis (Kamakura 
et al., 1985). The calpain cleavage sites for the neurofilament isoforms have not been 
established in mammals, except for two sites (after lys 467 and lys 516) identified in 
bovine NFM (Shaw et al., 2004). 
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In addition to neurofilaments, microtubules may be degraded during GDC (Donat 
and Wisniewski, 1973; Schlaepfer, 1974). However, Zhai and colleagues (2003) have 
suggested that the early loss of microtubules may not be due to degradation, but to 
depolymerization, at least in vitro. Some but not all studies support that tubulin is a 
calpain substrate (Billger et al., 1988; Malik et al., 1987; Sandoval and Weber, 1978). In 
vitro calpain proteolysis of tubulin results in a ~50 kDA fragment that is quite similar in 
size to intact tubulin (Billger et al., 1988). Calpains retard the assembly and promote the 
disassembly of purified microtubules. Purified tubulin subjected to in vitro proteolysis by 
calpain forms large aggregates without any obvious structure (Billger et al., 1988). 
Microtubule depolymerization may also be due to proteolysis of microtubule associated 
proteins (MAPs), which are critical for microtubule stability (Gordon-Weeks and Fischer, 
2000; Johnson et al., 1989; Maccioni and Cambiazo, 1995; Sandoval and Weber, 1978; 
Weingarten et al., 1975). MAP1 and tau are calpain substrates, and their proteolysis 
generates multiple fragments (Fischer et al., 1991; Johnson et al., 1989; Sato et al., 
1986; Yang and Ksiezak-Reding, 1995). When a purified mixture of microtubules and 
MAPs is incubated with calpain, MAP1 is degraded and no longer binds to microtubules 
(Billger et al., 1988). Adding further complexity, microtubule depolymerization may result 
directly from elevated Ca2+ or by Ca2+ activation of calmodulin (Gaskin et al., 1975; Job 
et al., 1981; Keith et al., 1983; O'Brien et al., 1997). In the injured axon, it is difficult to 
tease apart the role of calpains from the other effects of elevated Ca2+. The mechanism 
of microtubule loss in GDC may be multifactorial.  
 
A.3. Calpains and GDC in Wallerian degeneration 
Direct evidence for the role of calpains in axonal degeneration initially came from 
in vitro studies. Reducing extracellular Ca2+ or application of various pharmacologic 
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calpain inhibitors decrease degeneration of transected neurites in dorsal root ganglia 
(DRG) cultures (George et al., 1995; Wang et al., 2000). The calpain inhibitor ALLN 
preserves neurofilament immunolabeling of transected neurites but not the axolemma as 
assessed by differential interference contrast microscopy or immunostaining for the cell-
surface antigen Thy-1.1 (Finn et al., 2000). In rat sympathetic superior ganglia (SCG) 
explants, ALLN prevents neurofilament degradation after neurite transection, but is 
unable to prevent microtubule fragmentation (Zhai et al., 2003). In contrast, EGTA and 
pharmacologic inhibitors to the ubiquitin-proteasome system (UPS) prevent both 
neurofilament degradation and microtubule fragmentation. One study did not find 
statistically significant protection of axotomized neurites of mouse cortical neurons with 
ALLN, but the wide variability may have obscured any drug effects (Kilinc et al., 2010). 
Care must be exercised when extrapolating these experimental findings to axons in vivo, 
as cultures consist of developmentally young neurons in a “simplified” extracellular 
environment. Pharmacologic calpain inhibitors are also known to inhibit proteases 
outside of the calpain family. Nonetheless, calpains may be important to some aspects 
of neurite degeneration. 
Two in vivo studies examining the role of calpains in axonal degeneration provide 
discordant results. Glass and colleagues (2002) studied sciatic nerve transection in 
C57Bl/6J mice. One hour after transection, there is increased Ab38, which specifically 
detects calpain-cleaved spectrin, signal in sciatic nerve homogenates. Ab38 signal is not 
detected at later time points, even though significant loss of NFL and ß-tubulin 
immunoreactivity occurs at 48 hours. Pretreatment with intraperitoneally administered 
calpain inhibitor leupeptin, which is continued throughout the survival period, does not 
prevent NFL degradation 72 hours post-sciatic nerve transection. These findings led the 
authors to suggest that calpains may not be directly responsible for cytoskeletal 
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degradation in vivo. The stability of the calpain-cleaved spectrin fragment or whether 
there was sufficient intra-axonal concentration of leupeptin is not known. Araújo Couto 
and colleagues (2004) applied the calpain inhibitor, Mu-F-HPh-FMK, directly to the optic 
nerve crush site in opossums. Ninety-six hours post-injury, there is statistically significant 
increase in axons with preserved cytoskeleton (mean±SD: 76±3.7% versus 67±4.2% 
nontreated injured) and reduction in degenerating axons with drug treatment. As Mu-F-
HPh-FMK also inhibits cathepsin L (product data sheet, Kamiya Biomedical, Seattle, 
WA), the use of an inhibitor to both calpains and cathepsins limits experimental 
interpretation. Based on these two studies, it is not clear if calpains are the causative 
agents of Wallerian degeneration in vivo. 
In 2005, Kerschensteiner and colleagues (2005) coined the term “acute axonal 
degeneration” (AAD) to describe the rapid fragmentation of axons immediately proximal 
and distal to the transection site. These investigators used transgenic mice that express 
green fluorescent protein (GFP) in DRG axons traversing superficially through the spinal 
cord. Within 5 minutes of transection, there is fragmentation and disintegration of 200-
300 µm of axon proximal and distal to the injury site. Application of a calpain inhibitor 
cocktail to the site of transection is completely protective. Another study provides indirect 
support for calpains by demonstrating that blocking Ca2+ entry after optic nerve crush 
ameliorated AAD (Knöferle et al., 2010). Even though AAD is temporally and spatially 
dissimilar to Wallerian degeneration, they may share similar molecular mechanisms. 
Based on the entire body of evidence presented here, I conclude that calpains 
may be important contributors to axonal pathology, particularly neurofilament 
degradation. Axonal injury and degeneration is likely multifactorial, and may include Ca2+ 
dependent non-calpain mechanisms, the ubiquitin-proteasome system or autophagy 
(Beirowski et al., 2010,; Knöferle et al., 2010; Zhai et al., 2003). The work presented in 
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this dissertation builds on these previous observations by showing a definitive causal 
role of calpains in cytoskeletal degeneration.   
 
B. Disruption of axonal transport and secondary axotomy after traumatic axonal injury 
B.1. Overview of traumatic axonal injury 
Axonal injury significantly contributes to blunt TBI severity and outcomes 
(Gennarelli et al., 1982; Medana and Esiri, 2003). In the mammalian CNS, immediate 
severing or transection of axons at the moment of trauma, known as primary axotomy, is 
an irreversible process, and is thought to only occur at the most severe mechanical 
strains (Maxwell et al., 1997). After blunt TBI, most of the injured axons are not torn at 
the moment of trauma, but a biochemical cascade is triggered within axons, ultimately 
disrupting their continuity (Jafari et al., 1997; Maxwell and Graham, 1997; Povlishock 
and Katz, 2005; Povlishock et al., 1997; Saatman et al., 2003). The progression from 
nondisruptively injured axons to overt axonal disconnection is termed secondary 
axotomy. Injured axons display impaired axonal transport and neurofilament alterations. 
After severe TBI in humans, axonal swellings due to the accumulation of organelles and 
other cytoplasmic proteins are seen within 6 hours of injury (Christman et al., 1994; 
Grady et al., 1993). There is also disruption of the ordered arrangement of 
neurofilaments, and as early as 12 hours post-injury, axonal bulbs are apparent 
(Christman et al., 1994). Axonal bulbs refer to swellings that have overtly disconnected 
from the rest of the axon. As axonal swellings and neurofilament alterations are 
potentially reversible or preventable, they are a major focus of TBI researchers. 
Disruption of axonal cytoskeleton and transport after trauma has been studied 
using a number of assays. Immunostaining for amyloid precursor protein (APP) and 
nonphosphorylated neurofilament, both of which undergo anterograde transport, labels 
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axonal swellings and bulbs at presumably focal sites of disrupted transport. Exogenously 
applied substances, such as horseradish peroxidase (HRP; Gennarelli et al., 1989; 
Povlishock et al., 1983) and fluorogold (Ma et al., 2012; Saatman et al., 2003), or 
overexpressed proteins like yellow fluorescent protein (Wang et al., 2011) have been 
used to detect axonal transport disruption.  
An attractive hypothesis is that microtubule loss impairs axonal transport 
(Maxwell, 1996; McCracken et al., 1999; Saatman et al., 2003). There is a dramatic loss 
of microtubules 15 minutes after optic nerve stretch in the guinea pig (Maxwell and 
Graham, 1997). The number of microtubules returns to baseline by 2 hours at the 
paranode and 4 hours at the node, but remains decreased for at least 24 hours at the 
internode. Importantly, internodal axonal swellings containing significantly reduced 
numbers of microtubules develops within 2 hours of injury. 
Neurofilament alterations are another commonly used histologic marker of TAI. 
All three neurofilament subunits have a central alpha-helical rod domain of about 300 
amino acids, flanked by a lobular amino-terminal head and non alpha-helical carboxy-
terminal side-arm domains. When neurofilament polymerizes to form long filamentous 
structures, the rod domains are normally masked by the phosphorylated sidearms. 
Binding of the antibody RMO-14 to the rod domain of NFM suggests that proteolysis or 
dephosphorylation of the sidearm has occurred (Büki et al., 2003; Maxwell et al., 1997; 
Povlishock et al., 1997; Stone et al., 2001). The presumed corollary of RMO-14 
immunolabeling on the ultrastructural level is neurofilament compaction, i.e. reduction of 
interneurofilament distance. RMO-14 immunoreactivity is prominent in the corticospinal 
tract and medial longitudinal fasciulus in animal models of DAI (Büki et al., 2003; Stone 
et al., 2001). It has been suggested that neurofilament alterations may impair 
axoplasmic transport (Christman et al., 1994; Smith and Meaney, 2000). However, 
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RMO-14 immunoreactive axons in the corticospinal tract do not stain with APP nor have 
evidence of organelle pooling, suggesting that neurofilament sidearm modifications may 
not by itself impair axonal transport (Stone et al., 2001).  
 
B.2. Role of calpains in traumatic axonal injury 
The molecular mechanisms responsible for impaired axonal transport, 
neurofilament alterations, and secondary axotomy have not been definitively established 
but calpains may play a role, particularly in the CNS. Whether these same events occur 
in the PNS is not as clear as injured PNS axons do not typically swell (Beirowski et al., 
2010). Axonal calpain activity has been reported to be elevated within minutes after 
experimental TAI (Büki et al., 1999b; Saatman et al., 2003). Calpain activity measured 
by Ab38 immunolabeling occurs in axons in the pyramidal tracts and medial lemnisci 15 
minutes after head acceleration injury in rats (Büki et al., 1999b). Ab38 immunoreactivity 
consistently colocalizes with RMO-14, suggesting that neurofilament modification may 
be due to calpains. After optic nerve stretch in the mouse, an in vivo model that isolates 
mechanical strain primarily to axons, calpain activity is detectable within axons 20-30 
minutes post-injury.  
Calpain inhibitor studies have provided more direct support for the causal role of 
calpains in TAI pathology. A single 30 mg/kg IV dose of MDL-28170 30 minutes prior to 
impact head acceleration injury in rats reduces APP and RMO-14 staining in the 
corticospinal tract and medial longitudinal fasciculus 2 hours post-injury (Büki et al., 
2003). Longer-term protection is also achieved with a single 30 mg/kg IV dose of MDL-
28170. Given 30 minutes prior to fluid percussion injury, there is decreased APP labeling 
and preservation of compound action potential in the corpus callosum up to 7 days after 
injury (Ai et al., 2007). The calpain inhibitor N-acetyl-leu-leu-methioninal administered via 
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continuous arterial infusion throughout the entire survival period reduces axonal 
swellings and bulbs in the corpus callosum and other white matter tracts 24 hours after 
cortical impact injury in the rat although quantification is not reported (Posmantur et al., 
1997). Transport disruption may be due to the loss of microtubules (Maxwell and 
Graham, 1997), and may be partly due to calpain proteolysis of tubulin and MAPs 
(Billger et al., 1988; Fischer et al., 1991; Johnson et al., 1989). Care must be taken when 
interpreting findings from global TBI models. In these models, it is often difficult to tease 
apart primary versus secondary injury to axons. Theoretically, the drug may directly 
protect non-axonal structures, which, in turn, may reduce the secondary injury seen in 
axons. The work presented in this dissertation builds on these previous observations by 
showing a definitive causal role of calpains in axonal transport disruption in an animal 
model that isolates mechanical strain primarily to axons.   
 
B .3. Commonalities and differences between Wallerian degeneration and TAI 
Calpains may directly contribute to cytoskeletal alterations and degeneration, and 
transport disruption after nerve transection and TAI. The duration and degree of 
elevation of calpain activity may be important in shaping the axonal pathology seen. 
Immediately after nerve transection, there is localized Ca2+ elevation that normalizes 
within a few minutes (Knöferle et al., 2010). This transient Ca2+ rise activates calpains, 
which may be responsible for AAD. However, Ca2+ homeostasis is quickly restored after 
a few minutes.  During the latency period, transected axons may experience focal 
disruption of Ca2+ homeostasis, resulting in axonal swellings, the signature pathology of 
TAI. After in vivo optic nerve transection, swellings distal to the transection site are seen 
as early as 4 hours in the mouse (Hasegawa et al., 1988) and 2 days in the rat  (Meller 
et al., 1994). I propose that the abrupt end to the latency period coincides with a 
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catastrophic yet unexplained failure to maintain intra-axonal Ca2+ homeostasis, resulting 
in sustained and robust calpain activity and GDC.  
TAI results in immediate Ca2+ elevations and pathologic calpain activity in 
localized regions of the axon likely causing transport disruption and swelling formation. 
The mechanism by which axonal swellings transition into bulbs is not known. Once 
axons become disconnected, Wallerian degeneration of the disconnected distal axon 
ensues. In addition to calpains, there may also be other axon degeneration pathways 
common to Wallerian degeneration and TAI. There may be Ca2+ dependent non-calpain 
pathways that are important in Wallerian degeneration and TAI (Staal et al., 2010; Zhai 
et al., 2003). In contrast, apoptotic mechanisms have been implicated in TAI (Büki et al., 
2000; Büki and Povlishock, 2006; Chen et al., 2004; Stone et al., 2002) but it is not likely 
to be important in degeneration of the transected axon (Finn et al., 2000; Kilinc et al., 
2010; Schoenmann et al., 2010; Whitmore et al., 2003). Inhibition of the ubiquitin-
proteasome system protected transected axons in vitro and in vivo (Zhai et al., 2003), 
but accelerated progression to secondary axotomy after in vitro axonal stretch injury 
(Staal et al., 2009). 
 
B.4. Intra-axonal sources of Ca2+ driving calpain activation  
As calpains absolutely require elevated Ca2+ for activity, the source of this intra-
axonal Ca2+ has garnered much scientific interest. Some studies implicate intracellular 
Ca2+ stores, while others extracellular Ca2+. Because of the complexity of manipulating 
Ca2+ in vivo, much of the work has been performed in vitro. Staal and colleagues (2007) 
deformed axonal bundles from rat cortical neurons using a fluid pulse, generating a 
transient 1-6% increase in original axon length. The axolemma remains impermeable to 
a 570 kDA molecular weight (MW) tracer for up to one hour post-injury. There is an 
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immediate rise in intra-axonal Ca2+ even though axons are bathed in Ca2+-free bath 
(Staal et al., 2010). The authors concluded that the source of intra-axonal Ca2+ is 
principally from intracellular stores.  
In a model where neurites from rat cortical neurons or a human neuronal cell line 
are stretched 70-75% beyond their initial lengths, a rise in intra-axonal Ca2+ is seen 
immediately, but can be blocked if extracellular Ca2+ or Na+ is removed or if neurons are 
pretreated with inhibitors to voltage-gated Na+ or Ca2+ channels or the Na+-Ca2+ 
exchanger (Iwata et al., 2004; Wolf et al., 2001). Na+ entry through mechanically 
sensitive Na+ channels may trigger an increase in intra-axonal Ca2+ via opening of 
voltage-gated Ca2+ channels or reversal of the Na+-Ca2+ exchanger. In this model, there 
is also no uptake of the 570 kDA tracer (Smith et al., 1999). These three studies 
implicate ion channels, and not the creation of traumatic defects (mechanoporation) of 
the axolemma, as the mechanism of extracellular Ca2+ entry.  
In vivo studies have added further complexity. Moderate fluid percussion injury 
(>2.0 atm), but not mild (1.5 to 2.0 atm), results in axolemmal permeability to HRP as 
early as 5 minutes after injury (Pettus et al., 1994). Post-injury calpain activity may 
further worsen axolemmal permeability in a feed forward spiral. Rats treated with MDL-
28170 prior to impact head acceleration injury have improved axolemmal integrity in the 
corticospinal tract 2 hours post-injury (Czeiter et al., 2009). The authors proposed that 
this might be due to a reduction in calpain-mediated proteolysis of spectrin, which is 
important for membrane stability.  
Studies of ischemic and hypoxic axons have also provided valuable insights 
about potential sources of intra-axonal Ca2+. Rise of intra-axonal Ca2+ in ex vivo optic 
nerves undergoing simulated ischemia is due to both extracellular Ca2+ and internal 
stores (Nikolaeva et al., 2005; Stys, 2005). During chemical inhibition of energy 
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metabolism in dorsal root myelinated axons or exposure of optic nerves to anoxia ex 
vivo, the Ca2+ overload occurs via reversal of Na+-Ca2+ exchanger, driven by axonal Na+ 
accumulation through voltage-gated Na+ channels (Petrescu et al., 2007; Stys and 
Lopachin, 1998). L-type and N-type Ca2+ channels have also been implicated (Brown et 
al., 2001; Fern et al., 1995). The source of the intra-axonal Ca2+ rise appears to depend 
on the injury and the model system, so directly targeting Ca2+ elevation may require 
different therapeutic interventions. 
 
C. Calpains may contribute to the disruption of specialized electrical domains, 
presynaptic terminals and electrophysiological function 
C.1. Overview of the axolemmal cytoskeleton and specialized electrical domains 
Actin and spectrin are major components of the axolemmal cytoskeleton, and 
contribute to the formation and stability of specialized electrical domains (Fig. 1; Isayama 
et al., 1991; Yang et al., 2004). Spectrins are comprised of α- and ß-subunits, and have 
binding sites for actin, ankyrin, and ion channels (Bennett and Baines, 2001). The α- and 
ß-subunits associate laterally to form antiparallel heterodimers, and the heterodimers, in 
turn, are assembled head-to-head to form heterotetramers. In humans, there are two α-
subunits (αI and αII), 4 ß-subunits (ßI, ßII, ßIII, and ßIV), and a ß-H subunit (also 
referred to as ßV). αII/ßII is located diffusely across the length of the axons but, 
depending on the nerve, can be enriched at paranodes and juxtaparanodes (Bennett 
and Baines, 2001; Ogawa et al., 2006), and in presynaptic compartments (Goodman, 
1999; Isayama et al., 1991; Schmitz, 2001). 
Action potential initiation, saltatory conduction, and synaptic transmission require 
specialized structures at the AIS, nodes and synaptic terminal, respectively. The voltage-
gated Na+ channels, Nav1.2 and Nav1.6, are localized to the mature AIS (Debanne et 
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al., 2011; Rasband, 2011). AnkyrinG (ankG) and ßIV spectrin link membrane proteins to 
the underlying actin cytoskeleton. ßIV spectrin is unique to the AIS and nodes (Schafer 
et al., 2009; Yang et al., 2004). Mature nodes share similar cytoskeleton organization as 
the AIS, except they lack Nav1.2 (Rasband, 2011; Schafer et al., 2009). AIS, nodes, and 
juxtaparanodes are enriched with K+ channels and cell adhesion molecules (CAMs). The 
two main CAMs at the AIS and nodes are neurofascin-186 and NrCAM, while the 
juxtaparanodes contain Caspr2, TAG-1 and ADAM22. In unmyelinated axons, which 
lack nodal domains, action potential propagation is supported by a homogenous 
distribution of Nav1.2 (Debanne et al., 2011). 
 
C.2. Calpain substrates in the axolemma and axolemmal cytoskeleton 
As discussed earlier, the proteolysis of αII-spectrin is a commonly used, sensitive 
and specific way to assay for in vivo calpain activity (Roberts-Lewis et al., 1994). 
Proteolysis of αII-spectrin renders its actin binding and crosslinking activity 
downregulatable by calmodulin (Harris and Morrow, 1990). The ß subunits are also 
calpain substrates (Löfvenberg and Backman, 1999; Schafer et al., 2009), and 
proteolysis of both subunits permanently impairs spectrin binding to actin regardless of 
calmodulin (Harris and Morrow, 1990). Disruption of the structure and function of these 
specialized electrical domains may be due to calpain proteolysis of the underlying 
axolemmal cytoskeleton. 
Intramembrane proteins that are calpain substrates include Nav1.2, L-type Ca2+ 
channel, and Na+-Ca2+ exchanger (NCX). Calpains cleave the Nav1.2 α-subunit at two 
predicted sites: within the I-II loop and II-III loop (von Reyn et al., 2009). There is 
possibly a third cleavage site but this is much less certain. The α-subunit contains the 
binding site for tetrodotoxin, the selectivity filter, the channel pore, and the structural 
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elements responsible for activation and inactivation. Inactivation refers to the process by 
which an open Na+ channel can close even in the presence of a maintained 
depolarization. After proteolysis, the majority of the channel stays in the membrane but 
the functionality of the remaining cleaved channel is not known (von Reyn et al., 2009). 
Iwata and colleagues (2004) suggested that proteolysis may prevent the inactivation of 
the channel. Isolated stretch of neurites in cortical cultures causes an immediate rise in 
intra-axonal Ca2+ that is dependent on Na+ influx (Iwata et al., 2004). Pretreatment with a 
protease inhibitor cocktail, which inhibits calpains among others, blocks the secondary, 
but not initial, rise in Ca2+. The authors proposed a feedforward pathway, where 
proteolysis of the Na+ channel results in loss of channel inactivation and more Na+ influx, 
which drives the secondary Ca2+ rise. 
Class C and D L-type Ca2+ channels have a homogenous distribution on 
myelinated optic nerve axons (Brown et al., 2001). These channels directly contribute to 
the intra-axonal rise of Ca2+ in simulated ischemia of optic nerves (Brown et al., 2001; 
Fern et al., 1995). In hippocampal neurons exposed to NMDA, the long form of the class 
C α1 subunit (210-220 kDA) is proteolyzed by calpains at its C-terminal domain, 
removing an estimated 250-300 amino acid residues (Hell et al., 1996). Work with C-
terminal truncation mutants of rabbit cardiac α1 subunits suggests that loss of the C-
terminus results in enhanced activation of the channel in response to depolarization (Wei 
et al., 1994). 
In normal physiology, the Na+-Ca2+ exchanger (NCX) couples Ca2+ extrusion to 
Na+ influx. The relative expression of the three isoforms (NCX1, NCX2, and NCX3) on 
axons and presynaptic terminals has not been firmly established (Lee et al., 2007; 
Minelli et al., 2007; Papa et al., 2003; Steffensen et al., 1997). In ischemia and isolated 
stretch of neurites, increased intracellular Na+ concentration may drive the NCX to work 
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in reverse mode, thus contributing to the rise in intracellular Ca2+ (Iwata et al., 2004; 
Petrescu et al., 2007; Stys and Lopachin, 1998). After brain ischemia and in glutamate 
treated neuronal cultures, NCX3 proteolysis is mediated by calpains (Bano et al., 2005). 
NCX1, but not NCX2, is also proteolyzed after brain ischemia but the causative agent is 
not known. One of the calpain cleavage sites of NCX3 is in close proximity to the high-
affinity Ca2+ binding regulatory domain, which is essential for modulating transport 
activity. NCX3 proteolysis results in loss of function, which is directly responsible for the 
excitotoxic death of cultured neurons. 
 
C.3. Evidence of calpain involvement in the disruption of specialized domains 
Evidence from various injury models suggests that calpains may be causative 
agents for the structural disruption of specialized electrical domains in axons. Disruption 
of the AIS after middle cerebral artery occlusion (MCAO) and in vitro oxygen glucose 
deprivation results from calpain proteolysis of ßIV spectrin and ankG (Schafer et al., 
2009). AIS disruption is also seen 5 days after optic nerve crush. AIS disruption, which 
could be ameliorated by MDL-28170 or calpastatin overexpression, is irreversible, 
results in loss of neuronal polarity and is independent of cell death. For unclear reasons, 
MCAO disrupts the organization of AIS but not nodes even though they share a similar 
composition (Schafer et al., 2009). In an ex vivo model of anti-ganglioside antibody-
mediated motor nerve terminal injury, the ultrastructure of the NMJ presynaptic 
components is preserved with pharmacologic calpain inhibition (O'Hanlon et al., 2003).  
In addition to the disruption of axolemmal membrane architecture in various 
injury models, axonal electrical and synaptic functions are also impaired. Optic nerve 
stretch results in abnormalities in visual evoked potential latency and amplitude several 
minutes after injury (Tomei et al., 1990), while fluid percussion injury causes 
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abnormalities in compound action potentials evoked in the corpus callosum 3 hours 
post-injury (Reeves et al., 2005). Compound muscle action potential (CMAP) is 
essentially lost 17 hours after sciatic nerve crush in mice (Moldovan et al., 2009). In spite 
of the many known calpain substrates that are critical for electrical function, 
pharmacologic calpain inhibitors do not protect action potential propagation after nerve 
injury (Jiang and Stys, 2000; Stys and Jiang, 2002). Even though calpain inhibition 
protects against neurofilament and spectrin breakdown in optic nerves exposed to ex 
vivo anoxia or oxygen-glucose deprivation, there is no electrophysiological protection 
(Jiang and Stys, 2000; Stys and Jiang, 2002). In ex vivo muscle preparations, the 
calpain inhibitor AK295 preserves immunoreactivity of Nav1.6, ankyrin G, Caspr, and 
neurofascin at the nodes, but does not afford protection of perineural currents or 
compound action potential in a model of anti-GD1a antibody directed complement 
activation (McGonigal et al., 2010). The authors suggested that the failure of the 
axolemma, when punctured by membrane attack complexes, to maintain ionic 
homeostasis may be the critical factor in mediating axonal conduction block in this 
model. The applicability of these findings to TAI or injury models, where the axolemma 
reseals or is not compromised, is not clear.  
 
VI. Thesis rationale 
Axonal injury and degeneration contribute to the morbidity and mortality of many 
human diseases, including TBI, SCI, cerebral ischemia, neurodegenerative diseases, 
and PNS disorders. These seemingly disparate disorders may share common molecular 
injury mechanisms. One such mechanism may be pathologic calpain activity within 
axons. Previous studies using various injury models have suggested that calpains may 
play a universal role in axonal injury and degeneration. However, definitive evidence for 
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a causal role of calpains in cytoskeletal degradation and axonal functional impairment is 
still required. I used two models of axonal injury, nerve transection and mechanical 
stretch of axons, to cause different pathologies in axons, in particular GDC and 
retrograde transport disruption. I hypothesized that calpains are causally responsible for 
both. Defining potentially universal mechanisms by which axons are injured may help 
our understanding of various human diseases in which axonal and synaptic dysfunction 
and degeneration are prominent. 
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Figure 1.1 
 
 
Fig. 1.1. Schematic of a myelinated axon. Proteolysis of known calpain substrates within 
the axon initial segment (AIS) and nodes (A) and axon cytoskeleton (B) may contribute 
to the structural and functional disruption seen in injured axons. The molecular 
composition of AIS and nodes is similar. Represented locations of proteins are not 
exhaustive. Cav, Ca2+ channel, Nav, Na+ channel; NCX, Na+-Ca2+ exchanger. 
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CHAPTER 2: 
 
Role of calpains in axonal and synaptic 
degeneration in the central and peripheral 
nervous systems 
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Abstract 
 In both the central nervous system (CNS) and peripheral nervous system (PNS), 
transected axons undergo Wallerian degeneration. Early pathology includes denervation 
of the synapse, failure of synaptic transmission, and granular disintegration of the axonal 
cytoplasm (GDC). The evidence that the Ca2+-dependent protease calpains contributes 
to GDC is not compelling. To test the hypothesis that calpains play a causal role in 
axonal and synaptic degeneration in vivo, we studied transgenic mice that overexpress 
human calpastatin (hCAST), an endogenous calpain inhibitor, in optic and sciatic nerve 
axons. Five days after optic nerve transection and 48 hours after sciatic nerve 
transection, there was robust neurofilament light chain proteolysis in wild-type controls 
that was prevented in hCAST transgenic mice. In addition, there was significant 
morphological protection of sciatic nerve axons after transection in hCAST expressing 
mice (90.2±6.5% versus 18.3±5.3% p<0.0001). There was also a trend towards 
morphological protection in optic nerves (p=0.03). Although hCAST expression 
preserved the morphological integrity of neuromuscular junctions after sciatic nerve 
transection (71.3±10.3% of NMJ had greater than 50% but not complete innervation 
versus 11.8±7.9% wild-type, p<0.001), there was no improvement in compound muscle 
action potential amplitudes (p=0.51). These results provide direct evidence that calpains 
are responsible for the structural degeneration of axons and synapses seen in Wallerian 
degeneration. 
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Introduction 
In 1849, Augustus Waller made the seminal observation that after nerve 
transection, the distal portion undergoes progressive degeneration (Waller, 1850). 
Wallerian degeneration occurs in both the central nervous system (CNS) and peripheral 
nervous system (PNS). After transection, there is a latency period of varying lengths, 
when the distal nerve is morphologically normal and electrically excitable (Wang et al., 
2012). Early pathological changes include denervation of the pre-synaptic terminal, 
failure of synaptic transmission, and granular disintegration of the cytoplasm (GDC), in 
which the organelles and cytoskeletal components appear to disintegrate (Miledi and 
Slater, 1970; Okamoto and Riker, 1969). Both CNS and PNS axons undergo GDC but a 
subpopulation of transected CNS axons alternatively undergoes “dark” degeneration, 
where the axoplasm fills with electron-dense material that obscures the cytoskeleton 
(Bignami et al., 1981; George and Griffin, 1994; Marques et al., 2003).  
Calpains are a family of Ca2+-dependent nonlysosomal proteases, and have 
been implicated in axonal degeneration. Their physiologic roles include cytoskeletal 
remodeling, cell-cycle regulation, signal transduction, vesicular trafficking, apoptosis, 
and necrosis (Zatz and Starling, 2005). The two ubiquitous calpains, µ- and m-calpain, 
are heterodimers consisting of 80 kDa catalytic subunits that are ~50% identical in their 
amino acid sequence, and a common 30 kDa regulatory subunit. The major functional 
difference between µ- and m-calpain is the in vitro Ca2+ concentration required for half-
maximal activity, 3-50 µM and 400-800 µM, respectively (Goll et al., 2003). Calpastatin, 
another member of the calpain family, is an endogenous inhibitor completely specific for 
calpains and does not inhibit any other protease (Goll et al., 2003). 
Evidence linking calpains to Wallerian degeneration primarily comes from in vitro 
studies using pharmacologic inhibitors. Pharmacologic calpain inhibitors prevent neurite 
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fragmentation and disappearance, or loss of neurofilament immunostaining after neurite 
transection of dorsal root ganglia (DRG) and sympathetic superior ganglia (SCG) 
explants (Finn et al., 2000; George et al., 1995; Wang et al., 2000; Zhai et al., 2003). All 
pharmacologic calpain inhibitors, however, inhibit other proteases (Goll et al., 2003). 
Two in vivo studies examining protection of transected CNS and PNS axons with calpain 
inhibitors were inconclusive (Araújo Couto et al., 2004; Glass et al., 2002).  
The present study seeks to expand our understanding of the role of calpains in 
axonal and synaptic degeneration in the adult CNS and PNS. We hypothesized that 
specific calpain inhibition within axons would provide biochemical, morphological and 
functional protection after axonal transection in vivo. Previous in vitro studies must be 
interpreted cautiously as explants usually consist of developmentally young neurons 
lacking the complex supporting structures seen in vivo. In addition, earlier studies relied 
on pharmacologic calpain inhibitors. Therefore, our strategy utilized adult transgenic 
mice that overexpress human calpastatin (hCAST) within the axons of the optic and 
sciatic nerves. Mechanistic insight into axonal and synaptic degeneration is likely 
relevant to many acquired and inherited disorders, such as traumatic brain injury, spinal 
cord injury, neurodegenerative diseases, and demyelinating and hereditary 
neuropathies.
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MATERIALS AND METHODS 
All animal procedures were performed in accordance with NIH guidelines for the care 
and use of laboratory animals and were approved by the Institutional Animal Care and 
Use Committee at the Universities of Pennsylvania and Kentucky. 
 
Generation of hCAST transgenic mice 
Mice overexpressing hCAST under the primarily neuronal prion promoter were 
created on a FVB/N background. Mice were maintained as heterozygotes by breeding 
purchased wild-type FVB/N females (Harlan Labs, Indianapolis, IN) with hCAST 
transgenic male heterozygotes. For experimental procedures, adult transgenic and wild-
type littermates (4-6 months of age) were used. 
 
Immunohistochemistry of nerves and brain 
 Mice were anesthetized with ketamine and xylazine. They were transcardially 
perfusion fixed with 1x PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer 
(PB, ph 7.4). Optic and sciatic nerves were removed and postfixed in perfusate at 4°C 
for 1 hour, then cryoprotected in 30% sucrose. Brains were taken from non-perfused 
animals, and postfixed in 4% paraformaldehyde in 0.1 M phosphate buffer at 4ºC for 6 
hours prior to cryoprotection in sucrose. Ten µm thick longitudinal and cross-sections of 
nerves and 20 µm thick coronal sections of brain from wild-type and hCAST transgenic 
mice were cut on the cryostat. Brain and nerve sections were blocked in 3% normal goat 
serum and 0.1% triton in 1x PBS for 30 min at room temp. Nerve sections were 
incubated with antibodies targeting neuron-specific class III ß-tubulin (Tuj1; 1:2000, 
Covance, Emeryville, CA) or calpastatin (sc-20779; 1:250; Santa Cruz Biotech, Santa 
Cruz, CA) in blocking solution at 4°C overnight. Brain sections were incubated with 
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antibodies targeting neuron-specific class III ß-tubulin (PRB-435P; 1:5000, Covance) or 
human calpastatin (MAB3084; 1:1000; Millipore, Billerica, MA). The following day, the 
sections were washed with 1x PBS, incubated with alexa secondary antibodies (Life, 
Grand Island, NY) for 1 hour at room temp, rinsed in PBS, and coverslipped with 
Fluoromount G (Electron Microscopy Sciences, Hatfield, PA). 
 
Ex vivo calpain inhibition assay of cortical homogenates 
 Under ketamine and xylazine anesthesia, wild-type and hCAST transgenic mice 
were decapitated and the brain removed and placed on ice. The cortex was isolated and 
sonicated on ice in 25 mM hepes, 1 mM EDTA, 5 mM B-mercaptoethanol, and 0.1% 
CHAPS (pH 7.4). The homogenates were frozen, so that all samples could be assayed 
in triplicate on the same microtiter plate. Protein concentration was determined using the 
Bradford assay. Reactions for calpain activity assay contained 100 µg of cortical 
homogenate, 5 nM calpain 1 (EMD) and 200 µM Suc-Leu-Tyr-MNA (MP Biomedicals, 
Solon, OH) in a total volume of 200 µl. The room temp reaction was started by adding 
CaCl2 to a final concentration of 5 mM. Time-dependent substrate hydrolysis was 
measured on a microplate reader (Turner Biosystems, Sunnyvale, CA; 365 nm 
excitation, 410-460 nm emission).  
 
In vitro calpain digest of optic and sciatic nerves 
 Optic and sciatic nerves were removed from 3 wild-type FVB/N mice, pooled, and 
sonicated on ice in 25 mM HEPES, 1 mM EDTA, 5 mM B-mercaptoethanol, and 0.1% 
CHAPS (pH 7.4) with phosphatase inhibitor cocktail (Roche, Indianapolis, IL). Protein 
concentration was determined using the Bradford assay. Reactions contained 1.9 µg/µl 
of nerve homogenates and some combination of 1 µM calpastatin peptide (EMD, 
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Gibbstown, NJ), 100 nM human erythrocyte µ-calpain (EMD), or 100 nM recombinant m-
calpain (EMD). The room temp reaction was started by adding CaCl2 (or equal volume of 
water) to a final concentration of 5 mM. Reactions were stopped at designated times by 
adding 2x loading buffer and heating to 95ºC for 5 min. 
 
Unilateral optic nerve transection 
 Adult mice were anesthetized with ketamine (100 mg/kg intraperitoneal, IP) and 
xylazine (10 mg/kg IP), pretreated with buprenorphine (0.05 mg/kg IP) and placed on a 
heating plate. Bupivacaine anesthetic drops were applied to the eyes. Under a binocular 
operating microscope, the conjunctiva was separated from the sclera superiorly and the 
optic nerve exposed by blunt dissection. The optic nerve was transected ∼1 mm behind 
the globe using Vannas spring scissors (Fine Science Tools, Foster City, CA). 
Erythromycin ophthalmic ointment was applied to both eyes. Mice received 
buprenorphine (0.05 mg/kg IP) every 12 hours for up to a total of 4 additional doses. 
 
Unilateral sciatic nerve transection 
 Sciatic nerve transection was performed 72 hours after optic nerve transection. 
The lower back was shaved and cleaned with betadine. The skin was incised then the 
sciatic nerve was exposed by blunt dissection and transected at the internal obturator 
tendon using Vannas spring scissors. For longer survival times, a 10-0 ligature was 
applied to the proximal stump, and sutured to the surrounding tissue to prevent axonal 
growth into the distal segment. The skin was then sutured. Mice received buprenorphine 
every 12 hours for up to a total of 4 additional doses. For electrophysiological and NMJ 
experiments, the animals did not receive optic nerve transection. 
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Ultrastructural analysis of nerves 
 Anesthetized mice were transcardially perfusion fixed with 2% paraformaldehyde 
and 2% glutaraldehyde in 0.1 M PB (pH 7.4). The nerves were quickly removed, then 
postfixed in perfusate solution for at least 4 hours at 4°C. Nerves were osmicated and 
dehydrated. They were treated twice with propylene oxide for 5 min, incubated 
sequentially with Embed 812:propylene oxide mixtures (1:1 and 2:1) and pure Embed 
812 mixture (Electron Microscopy Sciences) overnight. Tissues were then embedded in 
fresh Embed 812 mixture at 60°C for 48 hr. Cross-sections were cut at a thickness of 1 
µm, stained with toludine blue and examined by light microscopy.   
Nerve cross-sections were imaged using a FEI Tecnai 12 electron microscope 
equipped with a Gatan 895 US1000 2k x 2k CCD camera. Optic nerves were analyzed 
0.5 mm from the optic chiasm, while sciatic nerves were analyzed 8.5 mm distal to 
transection. Systemic sampling of the nerve cross-sections was previously described in 
Ma et al. (2009) with minor modifications. For optic nerve scoring, images were captured 
at 3200x mag at 40 µm increments across and down the nerve. Sciatic nerve images 
were captured at 3200x mag at 30 µm increments. 
 
Optic nerve scoring (5 days post-transection) 
Using Adobe Photoshop (San Jose, CA), a counting frame (as described by 
Gundersen, 1977) was overlaid on each image, and a blinded observer counted the 
number of intact myelinated axons with preserved cytoskeleton. Axons were counted as 
intact if (1) visible axoplasm had cytoskeletal preservation, and (2) <25% of the cross-
sectional area was filled with electron-dense material (“dark” degeneration). Myelin 
integrity was not a consideration as intra-axonal calpain inhibition is unlikely to directly 
affect myelin. Unmyelinated axons make up only a small fraction of total optic nerve 
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axons (<1%) in the adult rodent (Sugimoto et al., 1984), and were not scored. The area 
of the optic nerve cross-section was determined using NIH imageJ, and numbers were 
reported as total axons per nerve. Approximately 2% of the nerve cross-section was 
scored. 
 
Sciatic nerve scoring (48 hours post-transection) 
 Because sciatic nerve myelinated axons are significantly larger than optic nerve 
axons, very few axons are entirely in view at 3200x mag. Therefore, when sampling the 
sciatic nerve cross-section at 40 µm increments, a myelinated axon was selected for 
scoring based on proximity to a superimposed point. That axon was moved to the center 
of the viewing frame and imaged. This process was repeated until the entire cross-
sectional area was systematically sampled, as described above. Using DigitalMicrograph 
(Gatan, Pleasanton, CA), only myelinated axons were scored. A myelinated axon was 
considered intact if there was uniform, regularly spaced cytoskeleton in at least 50% of 
the visible axoplasm. Neither myelin integrity nor axoplasmic shrinkage was considered 
in the scoring of axons. The percent of myelinated axons that were intact is reported. 
About 80-140 myelinated axons were scored per sciatic nerve. 
 
Scoring of NMJ innervation 
After euthanasia, mice were decapitated, and the extensor digitorum longus 
(EDL) was carefully dissected from the leg and fixed in 4% paraformaldehyde in 0.1 M 
PB (pH 7.4) for 20 minutes, followed by 1x PBS rinses. Immunolabeling for NMJs in 
whole mount muscle preparation was performed as described by Bauder and Ferguson 
(in press) using antibodies targeting neurofilament (SMI-312R; 1:10000, Covance) and 
synaptic vesicles (SV2; 1:1000; Developmental Studies Hybridoma Bank, Iowa City, IA), 
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and TRITC conjugated α-bungarotoxin (1:200; Sigma-Aldrich, St Louis, MO). The 
antibodies targeting neurofilament and synaptic vesicles were visualized with a 
fluorescein conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch, 
West Grove, PA). As neurofilament is not present in the NMJ, immunoreactivity at the 
NMJ was due to SV2 labeling. Neurofilament immunoreactivity was used to confirm 
antibody penetration into muscle tissue. Approximately 125-150 NMJs per muscle were 
scored by a blinded observer. NMJ innervation (percentage coverage of α-bungarotoxin 
by SV2 immunoreactivity) were visually estimated by a blinded observer and classified 
as (1) complete, (2) >50% but not complete, (3) <50% but not absent, and (4) absent.  
 
Electromyography 
 Fourteen hours after unilateral sciatic nerve transection, electromyography 
(EMG) was performed as described by Osuchowski et al. (2009). Mice received IP 
ketamine and xylazine and were placed on a heating plate. Rectal temperature was 
maintained >35ºC. For stimulation, 1-cm stainless steel electrodes were placed 
subdermally: the anode just lateral to the midline, with the tip inserted 1 mm caudal to 
the tail-base and advanced parallel to the spine, and the cathode ~3 mm lateral and 
parallel to the anode. One-cm subdermal needles inserted in the proximal thigh and into 
the heel served as the ground and reference electrodes, respectively. Each animal was 
simulated with incremental impulse intensity until a maximal and artifact-free compound 
muscle action potential (CMAP) motor response was evoked. Recordings were obtained 
using a 9.5-mm gold plated ear clip electrode (Electrode Store, Enumclaw, WA). The 
electrode was coated with an electrode gel and placed over the distal foot. This location 
likely resulted in recordings from multiple small foot muscles. Manipulating the electrode 
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on the foot was performed to ensure maximal CMAP. Measurements were made for 
both legs using a Nicolet/VIASYS Viking Quest machine. 
 
Processing of nerves for western blot 
Under ketamine and xylazine anesthesia, mice were decapitated. The optic 
nerve, after discarding the proximal ∼0.5 mm (transection site), was sonicated in 50 mM 
tris (pH 7), 150 mM NaCl, 1% triton, and 2 mM EGTA. Approximately 8.5 mm of the 
sciatic nerve distal to the transection was removed from the body. The proximal ∼1 mm 
(transection site) was discarded, and the remaining was sonicated in 50 mM tris (pH 
7.5), 1% SDS, and 2 mM EDTA. The homogenate was centrifuged at 16100 g, and the 
pellet discarded. Buffers contained protease inhibitor cocktail (Roche, Indianapolis, IN). 
Corresponding lengths of contralateral nerves were used as uninjured controls. 
 
Western blot 
Protein concentration was quantified using Bradford assay. Proteins were 
separated using SDS-PAGE on a 4-20% tris-glycine gel, transferred to nitrocellulose 
membrane, and probed for neurofilament light (NFL; PRB-574C; 1:20000; Covance), 
calpastatin (sc-20779; 1:1000), or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; PA1-988; 1:1000; Thermo Scientific, Rockford, IL). Blots were visualized with 
enhanced chemiluminescence (HRP-conjugated secondary antibodies and enhanced 
chemiluminescence substrate from Perkin Elmer, Waltham, MA). Blots were then rinsed, 
and amido black staining was performed for loading control. 
 
Statistical analysis 
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Student’s t-tests were used to compare the slopes (fluorescence over time) 
obtained in the CAST activity assay and to compare wild-type and transgenic injured 
muscle for NMJ innervation. A p-value < 0.05 was considered statistically significant. In 
all other analysis, ANOVA in repeated measures was performed. A p-value <0.05 for 
main effects and <0.2 for the interaction spaces were considered statistically significant. 
Pairwise comparisons were specified a priori and were accomplished using the t-test 
with pooling of the variance. Significance levels for pairwise comparisons were adjusted 
for by using the Bonferroni correction. There were three pre-planned comparisons: 
uninjured wild-type versus transgenic, injured versus uninjured wild-type, and injured 
wild-type versus injured transgenic. For these 3 pairwise comparisons a p<0.017 was 
considered significant. Data are presented as means and standard deviations. All data 
were analyzed using SAS statistical software (version 9.2, SAS Institute, Cary NC).  
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RESULTS 
Characterization of hCAST transgenic mice 
We first characterized expression of the hCAST protein in central and peripheral 
nerves by performing western blots of cortical, optic nerve, and sciatic nerve 
homogenates. There was high expression of hCAST in all three tissues from hCAST 
transgenic mice but not in tissues from their wild-type littermates (Fig. 1A). We then 
performed immunohistochemistry to confirm our western blot results and further 
characterize calpastatin (CAST) localization. Overexpressed CAST was detectable in 
cortical neurons and neuropil, and optic and sciatic nerve axons (Fig. 1B). 
The functionality of the expressed hCAST was assessed using a fluorogenic 
substrate microplate assay (Fig. 1C). The proteolysis of Suc-Leu-Tyr-MNA resulted in 
increasing fluorescent signal. We compared cortical homogenates from transgenic mice 
with their wild-type littermates. Homogenates from hCAST mice robustly inhibited 
exogenous calpain activity (p<0.0001). Omitting the fluorogenic substrate or CaCl2 
resulted in no increase in fluorescence over time. Omitting exogenous calpain resulted in 
a slight increase in fluorescence only in wild-type homogenates, likely due to 
endogenous calpains (data not shown). In summary, hCAST was robustly expressed in 
cortex, and optic and sciatic nerve axons, and overexpressed hCAST retained its ability 
to inhibit calpain.  
 
In vitro calpain digest of optic and sciatic nerves yields unique neurofilament 
fragments 
 To determine whether the levels of hCAST overexpression adequately inhibited 
axonal calpains, we searched for a unique “signature” of intra-axonal calpain activity. We 
sought to identify a substrate in nerves that was present exclusively within axons and 
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that generated stable proteolytic fragments when cleaved by calpains. This would make 
it possible to measure both loss of intact protein and accumulation of the reaction 
product. Loss of intact neurofilaments, which are well-known calpain substrates, is a 
commonly used outcome measure for axonal degeneration (Glass et al., 2002). We 
investigated NFL (Fig. 2). Calpain activity is recognized by both its absolute dependence 
on Ca2+ and inhibition by CAST. Unlike all pharmacologic inhibitors, CAST is completely 
specific for calpains and does not inhibit proteases from other families (Glass et al., 
2002). Using an antiserum against full-length recombinant mouse NFL, we identified 
multiple fragments in calpain digests of optic and sciatic nerves from wild-type mice. 
Endogenous calpain activity resulted in time-dependent loss of intact NFL and 
generation of a ∼55 kDA fragment. Both the loss of intact and generation of the ∼55 kDA 
fragment was completely blocked by 1 µM CAST peptide. The addition of either 
exogenous µ- or m-calpain (5 nM) accelerated the loss of intact NFL and generated the 
∼55 kDA fragment as well as several lower molecular weight fragments, notably at ∼22 
and ∼40 kDA.  
 
Time course of axonal degeneration after optic and sciatic nerve transection  
Our next step was to determine the optimal time point in vivo to compare axonal 
degeneration in the CNS and PNS in hCAST versus wild-type mice. We performed 
unilateral transection of optic and sciatic nerves in wild-type mice, and sacrificed them at 
predetermined intervals. NFL western blot demonstrated significant loss of intact NFL 5 
days after optic nerve transection and 48 hours after sciatic nerve transection (Fig. 3). 
The NFL fragments generated are of similar sizes as those seen in the in vitro calpain 
digest of nerve homogenates. The ∼22 and ∼40 kDa fragments were the most 
prominent. The ∼55 kDa fragment was not consistently seen in degenerating optic or 
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sciatic nerves, and may represent a less stable transition fragment. Morphological 
analysis by electron microscopy confirmed significant axonal degeneration 5 days and 
48 hours after optic and sciatic nerve transections, respectively (Fig. 5). Therefore, we 
chose these time points to measure the effect of hCAST overexpression.  
 
Biochemical effect of hCAST on CNS and PNS axonal degeneration 
 Our next experiment was to determine if hCAST overexpression can block NFL 
proteolysis and the generation of the ∼22 and ∼40 kDa fragments. Human CAST 
transgenic mice and their wild-type littermates underwent unilateral optic nerve 
transection, followed by unilateral sciatic nerve transection 72 hours later. This strategy 
made the most efficient use of animals, and transecting optic nerves prior to sciatic 
nerve transection did not affect NFL proteolysis in sciatic nerves (data not shown). Five 
days and 48 hours after optic and sciatic nerve transections, respectively, mice were 
sacrificed and fresh nerve tissue harvested for analysis. There was no difference in 
intact NFL levels between wild-type and hCAST mice in uninjured optic (p=0.21) and 
sciatic nerves (p=0.60). There was significant loss of intact NFL and generation of the 
∼22 and the ∼40 kDa NFL fragments after optic and sciatic nerve transections in wild-
type mice. However, hCAST overexpression protected against NFL proteolysis in 
transected optic and sciatic nerves. Five days after optic nerve transection, there was a 
45.6±25% loss of intact NFL in wild-type mice (p=0.005). There was preservation of 
intact NFL (p=0.007) and reduction in the generation of both the ∼22 (p<0.0001) and ∼40 
kDa (p<0.0001) NFL fragments in hCAST mice, as compared to the wild-type controls. 
Forty-eight hours after sciatic nerve transection, there was preservation of intact NFL 
(p=0.0008) and reduction in the generation of both the ∼22 (p<0.0001) and ∼40 kDa 
(p<0.0001) NFL fragments in hCAST mice, as compared to the wild-type controls.  
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Effect of hCAST on morphological degeneration of CNS and PNS axonal 
cytoskeleton 
Next, we determined if calpain inhibition afforded cytoskeletal protection to 
transected CNS and PNS axons. Five days after unilateral optic nerve transection, 
animals were perfused for ultrastructural analysis of the nerves (Fig. 5). In uninjured 
optic nerves, there were a total of 50,775±4345 and 54,912±2797 myelinated axons in 
wild-type and hCAST mice, respectively (p=0.011; Fig. 6). After transection, there were 
10,556±2229 axons remaining in wild-type mice (p<0.0001 compared to contralateral 
uninjured side). There was a trend towards protection in hCAST mice (13919±3369 
axons) compared to their wild-type littermates (p=0.03). For these 3 pairwise 
comparisons a p<0.017 was considered significant. In both wild-type and hCAST mice, 
most of the degenerating axons were diffusely filled with electron-dense material, 
consistent with “dark” degeneration. A smaller population of transected axons underwent 
GDC. 
 The peripheral nerves were examined 48 hours after unilateral sciatic nerve 
transection. Myelinated sciatic nerve axons were scored for the presence or absence of 
intact cytoskeleton. In uninjured nerves, essentially all axons (~99%) in wild-type and 
hCAST animals had preserved cytoskeleton (p=0.84 comparing uninjured wild-type with 
transgenic; Fig. 5 and 6). However, 48 hours after nerve transection in wild-type mice, 
only 18.3±5.3% of the axons had cytoskeletal preservation (p<0.0001 compared to 
uninjured wild-type). There was robust protection of transected axons in hCAST animals, 
with 90.2±6.5% of axons having cytoskeletal preservation (p<0.0001 compared to 
injured wild-type). In summary, there was robust morphological protection with specific 
calpain inhibition in the PNS, and a trend towards protection in the CNS. 
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Role of calpains in synaptic degeneration 
Because of the biochemical and morphological protection of PNS axons with 
calpain inhibition, we extended our investigation to the NMJ. The degeneration of the 
presynaptic terminal is one of the earliest pathology seen after nerve transection (Griffin 
et al., 1995). Eighteen hours after sciatic nerve transection, we removed the extensor 
digitorum longus (EDL) muscle for immunostaining of the NMJs using a synaptic vesicle 
marker (SV2; green) and TRITC-conjugated α-bungarotoxin (red; Fig. 7). SV2 and α-
bungarotoxin outline the presynaptic and postsynaptic terminals, respectively. In muscle 
innervated by uninjured nerves of wild-type and hCAST mice, essentially all NMJs had 
complete innervation, as defined by overlap of the SV2 and α-bungarotoxin labeling. 
Eighteen hours after transection, 0.1±0.3% and 2.8±3.2% of the NMJs in wild-type and 
hCAST mice, respectively, remained completely innervated (p=0.07). However, 
11.8±7.9% of NMJs in wild-type mice had >50% but not complete innervation compared 
to 71.3±10.3% of NMJs in the hCAST mice (p<0.001 versus wild-type injured) indicating 
partial NMJ protection with hCAST overexpression.  
 
Effect of calpains on synaptic dysfunction after PNS nerve transection 
 We have demonstrated biochemical and morphological protection of PNS axons, 
as well as structural preservation of NMJs, after nerve transection in hCAST mice. We 
next wanted to determine if hCAST also provided functional protection at the level of the 
synapse. Sciatic nerves were studied 14 hours after transection. At this time point, 
CMAP impairment likely represented synaptic dysfunction rather than failure of action 
potential conduction (Miledi and Slater, 1970; Okamoto and Riker, 1969; Ribchester et 
al., 1995). Fourteen hours after unilateral sciatic nerve transection, both nerves in the 
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same animal were electrically stimulated, and compound muscle action potentials 
(CMAP) were measured in the feet. There was no statistically significant difference in 
CMAP amplitudes between the uninjured nerves in the wild-type (15.2±1.8 mV) and 
hCAST mice (13.9±4.0 mV; p=0.54). Compared to the uninjured contralateral side, there 
was a 35±32% decrement in CMAP amplitude in transected nerves in wild-type mice 
(p=0.009). However, there was no statistically significant difference in CMAP amplitudes 
between the injured nerves in the wild-type (9.9±5.0 mV) and hCAST mice (7.1±5.9 mV; 
p=0.51). 
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DISCUSSION 
 In summary, these findings strongly support the hypothesis that calpains cause 
structural degeneration of transected PNS axons and their synapses. Calpain inhibition 
was not sufficient to preserve NMJ function, however. There was robust biochemical 
protection and a trend towards morphological protection after axon transection in the 
CNS with overexpression of the calpain-specific inhibitor calpastatin. Calpain inhibition is 
likely necessary, but not sufficient, to preserve axons and synapses, particularly in the 
PNS. Therefore, intra-axonal calpain activity may be a necessary therapeutic target to 
completely protect against axonal dysfunction and degeneration seen in many human 
diseases, such as CNS and PNS trauma, cerebral ischemia, neurodegenerative 
diseases, and peripheral neuropathies (Blumbergs et al., 1995; Glass, 2004; Medana 
and Esiri, 2003; Povlishock and Becker, 1985; Shy et al., 2002; Smith and Meaney, 
2000). 
 
Causal role of calpains in Wallerian degeneration  
Two in vivo studies examining the role of calpains in axonal degeneration 
provided inconclusive results. Pretreatment with intraperitoneally administered calpain 
inhibitor leupeptin, which was continued throughout the survival period, did not prevent 
NFL degradation 72 hours post-sciatic nerve transection (Glass et al., 2002). However, 
as leupeptin does not readily cross cell membranes, it is possible that there was not 
sufficient intra-axonal concentration of leupeptin to inhibit calpains. In contrast, topical 
application of the cathepsin and calpain inhibitor, Mu-F-HPh-FMK, directly to the optic 
nerve crush site in opossums was slightly protective (Araújo Couto, et al., 2004). Ninety-
six hours post-injury, there was statistically significant increase in axons with preserved 
cytoskeleton (76±3.7% versus 67±4.2% nontreated injured) and reduction in 
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degenerating axons in the drug treated group. As lysosomal cathepsins are important 
components of the autophagy pathway (Uchiyama, 2001), which has been implicated in 
axonal degeneration (Beirowski et al., 2010; Knöferle et al., 2010), the use of an inhibitor 
of both calpains and cathepsins limits experimental interpretation. 
Our study has several strengths, which allow us to conclusively determine that 
intra-axonal calpain activity is casually related to axonal degeneration in vivo. First, we 
identified and measured an axon-specific calpain reaction product (calpain-cleaved NFL) 
in nerves to prove the presence of pathologic calpain activity in Wallerian degeneration. 
Second, our strategy relied on overexpression of calpastatin, which only inhibits calpains 
and no other proteases (Goll et al., 2003). Finally, immunohistochemistry of nerves 
revealed calpastatin only in axons, limiting calpain inhibition to the axonal compartment. 
We furthered our understanding of calpains in Wallerian degeneration by 
examining the PNS synapse. CAST overexpression was able to reduce denervation of 
NMJs in vivo 18 hours after nerve transection. However, it is not clear if it is localized 
calpain activity within the NMJ presynaptic terminal that is directly responsible for 
denervation, or that denervation is a “byproduct” of axonal degeneration. Nevertheless, 
our data is consistent with and extends findings showing that pharmacologic calpain 
inhibitors protects NMJ cytoskeletal structure in an ex vivo model of anti-ganglioside 
antibody-mediated motor nerve terminal injury (O'Hanlon et al., 2003).  
 
“Dark” degeneration in the CNS 
Our observation that “dark” degeneration occurs in a large population of 
transected CNS axons but not in the PNS is consistent with previous reports (Bignami et 
al., 1981; George and Griffin, 1994; Marques et al., 2003; Narciso et al., 2001). The 
molecular mechanism and functional significance of “dark” degeneration is not known. 
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Spatially diffuse electron-dense material obscured visualization of cytoskeletal 
components, so “dark” degenerating axons were not scored as intact. All together, this 
data suggests that in hCAST mice, axons undergoing “dark” degeneration may have had 
preserved cytoskeletal ultrastructure, and that the molecular mechanism underlying 
“dark” degeneration and GDC are different.  
 
Calpain inhibition is not sufficient for protection of synaptic function 
We were unable to detect preservation of synaptic function measured at 14 hours 
after sciatic nerve transection in hCAST mice. We quantified NMJs at 18 hours because 
at this time point, there was sufficient denervation in wild-type mice to demonstrate an 
injury effect. NMJ innervation was preserved in hCAST mice 18 hours after sciatic nerve 
transection. In wild-type and hCAST mice, 11.8±7.9% and 71.3±10.3% of NMJs, 
respectively, had >50% but not complete innervation after transection (p<0.001). 
Potentially more informative is the observation that less than 3% of all NMJs in the 
transected side of hCAST and wild-type mice were morphologically normal. Because of 
the complexity involved in synaptic transmission, “slight” pathologic changes may render 
the synapse nonfunctional or dysfunctional.  
Calpain inhibition resulting in structural preservation without functional 
improvement has been reported in other nerve injury models. Pharmacologic calpain 
inhibitors protected against neurofilament and spectrin breakdown in optic nerves 
exposed to ex vivo anoxia or oxygen-glucose deprivation, but there was no 
electrophysiological preservation (Jiang and Stys, 2000; Stys and Jiang, 2002). In ex 
vivo muscle preparations, the calpain inhibitor AK295 preserved immunoreactivity of the 
Na+ channel Nav1.6, ankyrin G, Caspr, and neurofascin at the nodes, but did not afford 
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protection of perineural currents or compound action potential in a model of anti-GD1a 
antibody mediated injury (McGonigal et al., 2010).   
 
Conclusions 
 Understanding the potentially shared mechanisms that cause axonal dysfunction 
and degeneration may allow for common therapeutic targeting of axonal pathology in 
diverse human diseases. In this report, we have demonstrated that calpains cause 
axonal and synaptic degeneration during Wallerian degeneration. Preventing axonal 
injury and degeneration will likely require ameliorating pathologic calpain activity in the 
axon. 
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Figure 2.1 
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Fig. 2.1. Characterization of the hCAST transgenic mice. (A) Homogenates were 
prepared from the cortex, optic nerves and sciatic nerves of hCAST transgenic mice 
(TG) and wild-type (WT) littermates. Western blot was performed using antibodies 
targeting calpastatin (CAST; sc-20779) or glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Other abbreviations: M, male; F, female. (B) Coronal sections of the cortex 
and longitudinal and cross-sections (inset) of nerves were immunostained for neuron-
specific class III ß-tubulin and either calpastatin (sc-20779) or human calpastatin 
(hCAST; MAB 3084). Because brains were immersion-fixed, the focal intense green 
CAST staining in the wild-type mice represents native IgG in the vasculature. Scale bar 
= 25 µm. (C) Ex vivo analysis for functional hCAST in cortical homogenates from hCAST 
transgenic mice compared to wild-type littermates. Proteolysis of the fluorogenic calpain 
substrate Suc-Leu-Tyr-MNA results in increased fluorescent intensity. Fluorescent 
measurements were performed every 3 min over ~30 min. Addition of wild-type cortical 
homogenates (n=5) had no effect on exogenous calpain activity (5 nM), while addition of 
hCAST cortical homogenates (n=5) completely blocked proteolysis of the fluorogenic 
substrate. Error bars represent SD. *p<0.0001 compared to wild-type.
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Figure 2.2 
 
 
 
Fig. 2.2. Calpain degrades neurofilament light (NFL) in vitro. Optic and sciatic nerves 
were harvested from freshly sacrificed wild-type mice, sonicated on ice, and were 
digested the same day without freezing. Reactions contained some combination of 
calpastatin peptide (CAST), exogenous µ-calpain (µ-calp), exogenous m-calpain (m-
calp), or CaCl2. Reactions were stopped at specified time points by addition of loading 
buffer and heating to 95°C. Western blot was performed using an antiserum against 
full-length recombinant mouse NFL (PRB-574C; 1:20000). Calpain proteolysis 
resulted in loss of intact NFL, as well as generation of fragments with molecular 
weights of ~55, ~40, and ~22 kDa. 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Figure 2.3 
 
 
 
Fig. 2.3. Time course of NFL proteolysis after optic and sciatic nerve transection. 
Wild-type mice underwent unilateral optic and sciatic nerve transection and were 
sacrificed at the indicated times. The two left most lanes of each blot are controls in 
which optic or sciatic nerves underwent in vitro calpain digest (see Fig. 2). The “-” 
represent time 0 in the reaction that CaCl2 was omitted, while “+” was stopped 5 
minutes after adding µ- or m-calpain and CaCl2.  Western blot was performed using 
an antiserum against full-length recombinant mouse NFL (PRB-574C; 1:20000). Both 
optic and sciatic nerve transection resulted in NFL proteolysis, which generated 
similar sized fragments (~40 and ~22 kDa) as seen with the in vitro calpain digest. 
The latency period was longer after optic nerve transection. Other abbreviations: M, 
male; F, female. 
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Figure 2.4 
  
 
Fig. 2.4. Effect of hCAST overexpression on NFL proteolysis 5 days after optic nerve 
transection and 48 hours after sciatic nerve transection. (A) Western blot of homogenates 
of transected nerves (cut) and the contralateral uninjured nerves from wild-type (WT) and 
transgenic (TG) mice was performed using antiserum targeting NFL (PRB-574C; 1:20000). 
(B) Quantification of intact NFL and the ~40 and ~22 kDa proteolytic fragments. n=6-9 
mice per group. Human CAST blocks loss of full-length NFL, as well as the generation of 
the ~40 and ~22 kDa fragments in both optic and sciatic nerves. *p<0.01  **p<0.001 
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Figure 2.5 
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Fig. 2.5. Effect of hCAST overexpression on cytoskeletal structure 5 days after optic 
nerve transection and 48 hours and 5 days after sciatic nerve transection.  
Representative light and electron microscopic images of wild type (WT) and hCAST 
transgenic (TG) optic and sciatic nerves. An axon undergoing GDC is marked by single 
arrow, while axons undergoing “dark” degeneration are marked by double arrow. Scale 
bar=1 µm (EM), 10 µm (LM). 
    59 
Figure 2.6 
  
Fig. 2.6. Quantification of hCAST protection on cytoskeletal structure 5 days after 
optic nerve transection and 48 hours after sciatic nerve transection. (A) For optic 
nerves, quantification of intact myelinated axons in wild-type (WT) and transgenic 
(TG) was performed. Total myelinated axon counts per nerve were reported for 5 
days post-transected optic nerves and their contralateral uninjured controls. n=6-7 
mice per group. (B) For sciatic nerves (7 WT and 4 TG mice), myelinated axons 
were scored as intact or not, and the percentage intact was reported. Scoring was 
performed on 48 hrs post-transected sciatic nerves and their contralateral 
uninjured controls. There was statistically significant morphological protection of 
sciatic, but not optic, nerves with hCAST overexpression. Each circle represents 
an individual nerve, while horizontal bars represent means. *p<0.05 **p<0.0001 
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Figure 2.7 
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Fig. 2.7. Effect of hCAST overexpression on NMJ innervation 18 hours after sciatic 
nerve transection. (A) Representative images of NMJs 18 hours after transection in wild-
type and hCAST mice. SV2 (green) labels synaptic vesicles in the presynaptic 
compartment, while α-bungarotoxin (red) labels acetylcholine receptors on the 
postsynaptic membrane. NMJs in the uninjured contralateral side had consistently 
complete innervation (not shown). (B) NMJ were classified into one of 4 groups on basis 
of SV2 coverage of α-bungarotoxin labeling: (1) complete innervation, (2) ≥50% 
innervation but not complete, (3) <50% innervation, but not absent, (4) innervation is 
absent. The Y axis represents percent of NMJs in each group for an individual animal 
(n=7-10 mice per group). ~100-150 NMJs were scored on the injured side. For each 
animal, the percent from all 4 groups add up to 100%. Data from the uninjured side is 
not shown. hCAST overexpression preserved NMJ innervation 18 hours after sciatic 
nerve transection. *p<0.0001 
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Figure 2.8
  
 
 
Fig. 2.8. Effect of hCAST overexpression on motor nerve responses of transected and 
uninjured sciatic nerves. CMAPs were recorded from intrinsic foot muscles after 
supramaximal stimulation of the sciatic nerve immediately distal to the transection site. 
(A) Representative motor nerve responses from stimulation of wild type (WT) and 
hCAST transgenic (TG) sciatic nerves 14 hours after transection and their uninjured 
contralateral controls. Onset latency was measured from the initial negative deflection 
from baseline as marked by the plus sign. Amplitude was measured from baseline to 
peak as marked by the minus sign. (B) CMAP amplitudes are plotted for 10 WT and 9 
TG mice. Each circle represents an individual nerve, while horizontal bars represent 
means. *p<0.01 
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Immediate short-duration hypothermia provides 
long-term protection in an in vivo model of 
traumatic axonal injury 
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ABSTRACT 
A prospective, multicenter, randomized trial did not demonstrate improved 
outcomes in severe traumatic brain injured patients treated with mild hypothermia 
(Clifton, et al., 2001). However, the mean time to target temperature was over 8 hours 
and patient inclusion was based on Glasgow Coma Scale score so brain pathology was 
likely diverse. There remains significant interest in the benefits of hypothermia after 
traumatic brain injury (TBI) and, in particular, traumatic axonal injury (TAI), which is 
believed to significantly contribute to morbidity and mortality of TBI patients. The long-
term beneficial effect of mild hypothermia on TAI has not been established. To address 
this issue, we developed an in vivo rat optic nerve stretch model of TAI. Adult male 
Sprague-Dawley rats underwent unilateral optic nerve stretch at 6, 7 or 8 mm piston 
displacement. The increased number of axonal swellings and bulbs immunopositive for 
non-phosphorylated neurofilament (SMI-32) seen four days after injury was statistically 
significant after 8 mm displacement. Ultrastructural analysis 2 weeks after 8 mm 
displacement revealed a 45.0% decrease (p<0.0001) in myelinated axonal density in the 
optic nerve core. There was loss of axons regardless of axon size. Immediate post-injury 
hypothermia (32°C) for 3 hours reduced axonal degeneration in the core (p=0.027).  
There was no differential protection based on axon size. These results support further 
clinical investigation of temporally optimized therapeutic hypothermia after traumatic 
brain injury. 
 
KEYWORDS 
diffuse axonal injury; trauma; optic nerve; brain injury; hypothermia
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INTRODUCTION 
Currently, there are up to 6.5 million people in the United States living with the 
devastating physical, cognitive, and economic costs of traumatic brain injury (TBI) (NIH 
Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain injury, 
1999). An estimated 1.5 to 2 million cases of TBI occur each year in the US. It is 
predicted by the year 2020, TBI will be the third leading cause of death and disability 
each year in the world (Murray and Lopez, 1997). Traumatic axonal injury (TAI) 
contributes to the high rate of morbidity and mortality seen in severe TBI patients without 
space occupying lesions (Gennarelli, et al., 1982; Büki, et al., 2000). TAI is also believed 
to contribute to neurologic dysfunction after mild TBI. 
Studying TAI in the brain in vivo is complex as the traumatic event may 
proximately damage nuclei, dendritic fields, nerve tracts, and vasculature. The interplay 
between the various brain structures does not allow the investigator to isolate the 
specific mechanism and consequences of TAI. Direct injury to neuronal cell bodies and 
their dendritic fields, or glial cells and vasculature could have secondary effects on 
axons. Hemorrhage, elevated intracranial pressure and secondary ischemia are 
common after severe TBI, and are associated with poorer outcome. The difficulty in 
identifying specific neuronal cell bodies, which give rise to the axons of interest, limits 
experimental manipulation and interpretation. These limitations can be overcome in the 
optic nerve stretch model. The optic nerve shares similar properties with white matter 
tracts within the brain, including poor regenerative capacity, myelin sheath structure, and 
the presence of oligodendrocytes (Hirano and Lena, 1995; Cho, et al., 2005).  
In both humans and animals, trauma produces a rapid elongation of axons that 
generally does not cause primary axotomy (immediate tearing of the axon) but leads to 
progressive structural damage culminating in secondary axotomy (Jafari, et al., 1997; 
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Maxwell and Graham, 1997; Povlishock, et al., 1997; Saatman, et al., 2003; Povlishock 
and Katz, 2005). The distinction between primary and secondary axotomy is critical as 
primary axotomy in the CNS is considered irreversible. Impairment of axonal transport 
with subsequent accumulation of transported proteins and organelles, visualized using 
antibodies targeting amyloid precursor protein (APP) or neurofilament, are hallmarks of 
TAI. These sites of accumulated transported materials are known as axonal swellings. 
Eventually, a constriction may form near the swelling that progresses to axonal 
disconnection. This terminal increase in axonal diameter found after axonal 
disconnection is termed axonal bulb. 
Posttraumatic hypothermia has previously been shown to afford short-term 
axonal protection in models of TAI. Hypothermia (32.0-32.5°C) induced immediately and 
maintained for 4 hours after guinea pig optic nerve stretch reduced the number of β-APP 
labeled axons in animals sacrificed 4 and 8 hours after injury (Maxwell, et al., 1999; 
Maxwell, et al., 2005). Both studies also demonstrated preservation of cytoskeletal 
ultrastructure with hypothermia. Twenty-four hours after impact acceleration head injury 
in rats, there was a reduction in the number of APP-labeled axons with 1 hour of 
hypothermia (32°C) induced immediately after injury (Koizumi and Povlishock, 1998). 
Collectively, these past studies demonstrate the promise of using immediate mild 
hypothermia in mitigating TAI. However, the long-term benefits of hypothermia remain 
relatively unexplored. The previous studies counted APP-labeled axons, but this may 
significantly underestimate the overall magnitude of the axonal damage caused by 
trauma (Povlishock and Katz, 2005). It is not known whether all APP-labeled axons 
ultimately degenerate. 
 To address this issue, we developed a rat model of in vivo optic nerve stretch 
and demonstrated pathology similar to that observed in human TBI.  Furthermore, we 
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report for the first time sustained axonal preservation with immediate short-duration 
hypothermia after isolated axonal stretch injury in vivo.
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MATERIALS AND METHODS 
All animal procedures were performed in accordance with NIH guidelines for the 
care and use of laboratory animals and were approved by our Institutional Animal Care 
and Use Committee. 
 
Surgical Preparation for Optic Nerve Stretch 
 Adult male Sprague-Dawley rats (weight 300-400 grams) underwent general 
anesthesia with 2.5% isoflurane and were placed on a heating pad for surgery. 
Anesthesia was maintained via a nose cone. The cornea was anesthetized with 0.5% 
proparacaine, and the eye was kept moist at all times using sterile saline. The 
conjunctiva was separated from the sclera using an incision extending around the entire 
circumference of the eye except for the medial aspect (to minimize bleeding). A flexible 
thin ring-shaped plastic sling, which had a continuous loop of 4-0 monofilament nylon 
suture secured to it at two places 180° apart, was placed behind the eye. The sling had 
a break in its ring so the ends could be spread apart to allow placement behind the eye, 
and, after placement, the two ends of the ring were sutured together. The monofilament 
nylon loop was then attached to the optic nerve stretch device. 
 
Rat Optic Nerve Stretch 
To receive optic nerve injury, rats were placed in a stereotactic head holder that 
was positioned on the injury device (modified from Gennarelli, et al., 1989). We used 
rats, rather than mice, for these experiments because of the larger anatomic dimensions 
of the optic nerve, which allows for more precise control of the biomechanics of injury.  
For experiments characterizing SMI-32 immunohistochemistry, rectal temperature was 
used. For all other experiments, a probe placed in the temporalis muscle was used as a 
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surrogate for brain temperature and was maintained at 37.0–37.5°C at the time of injury. 
The head was positioned on the injury device such that the trajectory of the retro-orbital 
portion of the optic nerve was aligned with the stroke of the solenoid. The sling was 
connected to a force transducer (ELF T5000-a; Entran, Fairfield, NJ) mounted in series 
with a solenoid (Lucas-Ledex, Vandalia, OH) and in parallel with a displacement 
transducer (Trans-Tek Inc., Ellington, CT). To ensure consistent loading, a 30 g preload, 
measured by the force transducer, was placed on the nerve. The magnitude of the 
displacement was controlled by a micromanipulator that adjusts the distance traveled by 
the solenoid piston. Preliminary experiments in freshly sacrificed animals (part of the 
forebrain was removed so that the optic nerve was visualized during stretch) suggested 
that the distance the piston traveled was significantly more than the actual stretch of the 
optic nerve, consistent with past experiments in the guinea pig (Bain and Meaney, 
2000). The magnitude of optic nerve stretch reported here refers to piston displacement. 
Immediately after obtaining the preload, the solenoid was triggered to produce a rapid 
elongation of the nerve. For 8 mm piston displacement, the nerve was extended to the 
maximum displacement, held briefly, and then returned to its original pre-injury position 
within 75 milliseconds of initially activating the solenoid.  For the experiments in this 
report, the peak displacement occurred 25 milliseconds after triggering the solenoid, 
which is consistent with the timing of peak deformation that occurs within the brain 
during conditions that cause diffuse axonal injury (Meaney, et al., 1995). The plateau 
force, which was measured when the optic nerve was elongated to its maximum length, 
ranged from approximately 220 to 360 grams after accounting for the initial preload.  
Animals were excluded if injury to the globe or tearing of the optic nerve was 
apparent by visual inspection. In a subset of animals without obvious injury to the globe 
or optic nerve, pupils were dilated with 1% tropicamide for indirect fundoscopic 
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evaluation, which revealed normal retinal vessels without retinal hemorrhage, and rarely 
minimal intravitreal bleeding.  
The contralateral uninjured eye was used as a control. Sham surgery was 
performed on both optic nerves of two animals exactly as described except the solenoid 
was not triggered. All animals were recovered on a heating pad until the animal 
awakened from anesthesia, which usually took less than 5 minutes.  
 
Hypothermia 
All animals were subjected to unilateral 8 mm optic nerve stretch at 
normothermia (temporalis temperature between 37.0 and 37.5°C). The contralateral 
optic nerves in each animal served as controls. In the experimental group, hypothermia 
was induced immediately after stretch by fan, cold water spray and ice packs, and the 
animal was maintained at 32°C for 3 hours. Animals were then slowly rewarmed 1°C 
every 40 minutes to a temperature of 37°C before ending general anesthesia. The 
rewarming rate was selected based on a study by Maxwell, et al. (2005). Control animals 
were maintained at 37.5°C and kept anesthetized (1-1.5% isoflurane by a nose cone) for 
the same duration as the hypothermic animals. 
 
Bright Field Microscopy 
Tissue processing 
Four days after optic nerve stretch, rats, under deep isoflurane anesthesia, were 
perfused transcardially with cold 1x PBS followed by cold 4% paraformaldehyde in 0.1 M 
phosphate buffer. The optic nerves and eyes were exposed by dissection and separately 
removed from the head. Nerves were postfixed overnight before cryoprotection in 30% 
sucrose. 
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Immunohistochemistry of optic nerves for conventional bright field microscopy 
Optic nerves were cut longitudinally into 10 µm thick sections on a freezing 
sliding microtome. Nerve sections were mounted on microscope slides and allowed to 
dry over several days. Slides were rinsed in an ethanol series, pretreated in 5% H2O2 
and 83% methanol for 30 minutes at room temperature, and rinsed in 1x PBS. Sections 
were blocked in 3% goat serum and 0.1% triton x-100. The tissue sections were 
incubated overnight at 4oC with SMI-32 (1:2000; Sternberger Monoclonals Inc., 
Lutherville, MD, USA), which reacts with a non-phosphorylated epitope in neurofilament 
H. Accumulation of neurofilament highlights axonal swellings and bulbs. Mounted 
sections were then incubated with biotinylated goat anti-mouse secondary antibody 
(1:600) for 1 hour at room temperature. The enzymatic reaction was visualized using 3, 
3’ diaminobenzidine tetrahydrochloride. Slides were rinsed in xylene and coverslipped 
with DPX.  
 
Electron Microscopy 
Tissue processing 
Fourteen days after optic nerve stretch, rats, under deep isoflurane anesthesia, 
were perfused transcardially with 1x PBS followed by 2% paraformaldehyde and 2% 
glutaraldehyde in 0.1 M sodium cacodylate. Solutions were at room temperature. The 
brain was removed and the optic nerves were left in situ and postfixed overnight at 4oC. 
The optic nerves were then dissected from the skull, and allowed to remain in postfix 
until ready for processing. Nerves were ossicated, dehydrated in ethanol and propylene 
oxide. The prechiasmatic region of the optic nerve was embedded in epoxy resin and 
oriented specifically for cross-sections of the axons. Eighty nm thick sections were 
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stained with uranyl acetate and bismuth subnitrite for ultrastructural analysis.  One 
section from each nerve was analyzed for quantification of myelinated axons. 
 
Assessment of Histological Outcomes 
Axonal accumulation of non-phosphorylated neurofilament (SMI-32) 
Every eighth longitudinal section of the optic nerve (10 µm thick) was mounted on 
slides and dried for several days. The sections were labeled for SMI-32 as described 
above. Using a Leica DM4500B, 100x images of each section was captured by CCD 
camera. The number of discrete swellings and bulbs (diameter larger than 2.5 microns) 
in each mounted longitudinal section (starting from behind the eye to the optic chiasm) at 
a final magnification of 200x was counted by two independent blinded observers (except 
for sham injured nerves which were scored by one observer) (Figure 1). The total 
number of swellings and bulbs per each optic nerve was determined by each observer. 
The area of each mounted longitudinal section was calculated using NIH ImageJ and 
summed to get the total area scored. The number of swellings and bulbs per square mm 
was calculated for each optic nerve. Reported values for each nerve are the mean of two 
observers. 
Quantification of Myelinated Axons 
Optic nerve sections prepared for transmission electron microscopy were imaged 
using a JEOL JEM 1010 electron microscope aided by AMT HR-12 software and 
Hamamatsu CCD camera. An outline of the optic nerve cross-section was made and the 
x,y coordinates for the most superior and leftward points of the nerve border was 
recorded. The starting point for image capture was determined using the x from the most 
leftward coordinate and y from the most superior coordinate (Figure 2). Images were 
taken every 70 microns across until the rightward edge of the optic nerve was reached. 
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The camera was then moved 70 microns down, and images every 70 microns across the 
optic nerve were taken. This process was repeated until the entire optic nerve was 
systematically sampled (about 2% of the total area). 
A counting frame was then overlay on each image (final magnification of 
13,900x), and a blinded observer counted the number of myelinated axons that had 
some preservation of ultrastructure. We did not count unmyelinated axons as they 
comprise less than 1% of total axons in the rat optic nerve (Sugimoto et al., 1984). The 
area of the optic nerve was calculated using NIH imageJ, and axon counts were 
extrapolated so that total axons per optic nerve are reported.  
Each image had known x, y coordinates. The coordinates of all images from  
each optic nerve were plotted, and an ellipse was statistically fitted to the plot of the 
image coordinates. An ellipse can be described by the length of its major and minor 
axes. The length of the axes of the ellipse that result from the fit to the coordinate data 
represents the standard deviation of the data in the coordinate plane where the origin of 
the plane and the geometric center of the ellipse are coincident, and the major and minor 
axes are colinear with the axes of the coordinate system. To determine the scaled 
distance (i.e. percent) from the geometric center, an affine transform was performed and 
the coordinate system was scaled so that the ellipse becomes a circle (Figure 3). An 
affine transformation was performed in order to compensate for the varying aspect ratios 
(length of minor axis:length of major axis) of optic nerve cross-sections. In addition, it 
compensated for the different spatial orientation (location of centroid and rotation) of 
nerve cross-sections by statistically fitting the ellipse. The distance from the geometric 
center in the scaled coordinate system was used to rank the images. Images nearest to 
the center were considered be taken from the nerve center, while the rest of images 
were considered to be taken from the nerve periphery. Images were evenly divided 
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between center and periphery. When there were an odd number of images for a nerve, 
the additional image was classified as central. Axon densities are reported. 
C. Axon cross-sectional area 
A counting frame was overlay on each image taken from the central region of 
each optic nerve (final magnification of 13,900x). Using Adobe Photoshop® CS3 
Extended (v 10.0.1), a blinded observer used the quick selection tool to outline the 
axoplasmic area of each myelinated axon. The cross-sectional areas of approximately 
220-300 axons in the uninjured nerves and 40-280 in injured nerves were calculated. 
The axons in each uninjured normothermic optic nerve were divided into quartiles based 
on cross-sectional area. Using only the normothermic uninjured nerves, the mean 25th, 
50th, and 75th percentiles were established, and these values were subsequently used to 
separate the axons from the 24 optic nerves into four quartiles. The mean density of 
axons (6 optic nerves in each group) in each quartile is reported. The first quartile 
represent the smallest axons, while the fourth quartile represent the largest axons. 
 
Statistical Analysis 
The percentage axonal loss (the percent difference in axon number between the 
injured and its contralateral control optic nerve) between the normothermic and 
hypothermic groups was compared using a Student’s t-test. All other analyses were 
performed using analysis of variance (ANOVA) in repeated measures. A p-value <0.05 
for main effects and <0.2 for the interaction term was considered statistically significant. 
Post-hoc pairwise comparisons were accomplished using the t-test with pooling of the 
variance. Significance levels for post-hoc comparisons were adjusted for by using the 
Bonferroni correction. These levels varied depending on the number of preplanned 
pairwise comparisons made. Data are presented as means and standard deviation.  All 
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analyses were performed using SAS statistical software (Version 9.1, SAS Institute, 
Cary NC). 
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RESULTS 
Immunohistochemical analysis of axonal injury 
 In our preliminary experiments, 10 mm of stretch consistently tore the optic 
nerve. We therefore decided to compare number of axonal swellings and bulbs four days 
after 6, 7 and 8 mm of stretch (SEVERITY, n=3 animals per group). Overall, there was a 
significant INJURY effect (F=21.8, p=0.003) as well as an interaction 
(INJURY*SEVERITY, F=2.3, p=0.186). Because we wanted to determine a level of 
stretch severity that produced axonal injury, there were three pre-planned comparisons: 
each injury severity with their respective contralateral control nerves. A p<0.016 was 
considered significant. Axonal swellings and bulbs highlighted by SMI-32 labeling were 
detected after all three injury severities with 8 mm stretch reaching statistical significance 
relative to contralateral control nerves (p=0.009) (Figures 4 and 5). Injury was detected 
throughout the nerve, but was mainly concentrated at the prechiasmatic segment. In a 
separate experiment, the mean number (±SD).of swellings and bulbs per square mm 4 
days after sham surgery were 1.04±1.07. 
 
Hypothermia as a strategy for axonal protection after trauma 
Overall axonal loss 
Twelve rats (n=6 in both normothermia and hypothermic groups) were subjected 
to unilateral 8 mm optic nerve stretch at normothermia. Right optic nerves served as 
uninjured controls. In the TREATMENT group, hypothermia was immediately induced 
after stretch. Target temperature of 32°C was reached at a mean (±SD) time of 16.4±1.8 
minutes. An interim target of 34°C was reached at 10.8±2.0 minutes.  
Fourteen days after injury, rats were euthanized by perfusion fixation and optic 
nerve cross sections were prepared for transmission electron microscopy. There was a 
significant INJURY effect (F=20.4, p=0.001) and an interaction (INJURY*TREATMENT, 
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F=1.90, p=0.198). There were three pre-planned comparisons: injured versus control 
nerves in normothermic animals, injured versus control nerves in hypothermic animals, 
and normothermic injured versus hypothermic injured nerves. A p<0.016 was considered 
significant. The number of myelinated axons was 89214±3348 and 86485±4286 in 
normothermic and hypothermic control nerves, respectively. In injured optic nerves, the 
number of myelinated axons was 56220±19090 (37.1% decrease, p=0.002) in the 
normothermic group and 68922±20879 (20.4% decrease, p=0.051) in the hypothermic 
group (Figures 6 and 7A). The mean number of axons in hypothermic and normothermic 
injured nerves was not statistically different (p=0.14). Likewise, the overall percentage 
axonal loss after injury (pairing each injured optic nerve to its contralateral uninjured 
optic nerve) between the normothermic and hypothermic groups was not statistically 
different (p=0.14) (Figure 7B).  
Regionalization of stretch injury 
Based on our histologic observations, stretch injury appeared to cause axonal 
degeneration disproportionately in the central region of the nerve, leaving the periphery 
relatively preserved. Among normothermic animals, there was an INJURY effect 
(F=10.8, p=0.008) and an interaction (INJURY*REGION, F=10.5, p=0.01). There were 
two pre-planned comparisons, and p<0.025 was considered significant. We found, in 
normothermic animals, a statistically significant decrease in axonal density in the central 
region (45.0%, p<0.0001), but not periphery (16.6%, p=0.049) after 8 mm optic nerve 
stretch (Figure 8). We therefore decided to determine if immediate short-duration 
hypothermia was axonal protective in the optic nerve core after stretch. Comparing core 
axonal density between the normothermic and hypothermic injured nerves, only an 
interaction effect was noted (TREATMENT*REGION, F=3.64, p=0.086). There was one 
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pre-planned comparison, and p<0.05 was considered significant. Hypothermia protected 
against axonal loss in the optic nerve core 2 weeks after optic nerve stretch (p=0.027). 
Injury and hypothermic protection based on axon size 
 In normothermic rats, the mean percent decrease in axon density after optic 
nerve stretch was 38.5%, 37.2%, 37.7%, and 63.2% in the first, second, third and fourth 
quartiles, respectively (Figure 9). There was an INJURY effect (F=10.20, p=0.024) but 
not a QUARTILE effect (F=1.80, p=0.190) or an interaction (INJURY*QUARTILE, 
F=1.04, p=0.401). Stretch injury resulted in loss of axons regardless of axon size. 
Comparing hypothermic to normothermic animals, there was an interaction 
(INJURY*TREATMENT) effect for quartiles 2 (F=2.85, p=0.122) and 4 (F=3.40, p=0.095) 
but not for quartiles 1 (F=1.68, p=0.212) or 3 (F=0.00, p=0.991). However, post-hoc 
comparisons did not reveal any statistically significant difference between normothermic 
versus hypothermic injured nerves. Despite an overall treatment effect in the optic nerve 
core with hypothermia, there was no statistical difference between normothermic versus 
hypothermic injured nerves in any of the four quartiles.
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DISCUSSION 
Rat optic nerve stretch is a potentially powerful model to study the mechanism of 
TAI that occurs in human TBI. Our model replicates histopathologic outcomes, including 
SMI-32-labeled swellings and bulbs and axonal loss, seen in human TBI, and may 
possibly be used to study mild and severe TAI. Using this model, we were able to 
demonstrate robust regional long-term axonal protection with short-duration hypothermia 
initiated immediately after injury. The purpose of this investigation was primarily 
mechanistic. Our goals were to demonstrate that an intervention performed after trauma 
can provide long-term axonal protection, and that secondary axotomy is preventable. 
Defining the therapeutic window for post-injury hypothermia is a goal for future 
investigations. 
 
Our model replicates human pathology seen after TBI 
The characteristics of axonal injury and degeneration seen after optic nerve 
stretch mimic those found in established whole brain models of axonal injury, as well as 
in human brain after TBI. Axonal swellings and bulbs are hallmarks of TAI. In the rodent 
impact acceleration head injury model, APP, which undergoes anterograde transport like 
neurofilament, immunoreactivity was seen in the corticospinal tract and medial 
longitudinal fasciculus in injured rats (Büki, et al., 2003). Nonimpact rotational 
acceleration in primates and pigs resulted in axonal swellings and bulbs diffusely in 
white matter (Gennarelli, et al., 1982; Chen, et al., 1999). 
The pathology seen in the optic nerve stretch model also recapitulates what is 
seen in mild and severe TBI in humans. Using antibodies targeting neurofilament 
(including SMI-32), Grady, et al. (1993) demonstrated the progression from axonal 
swellings to bulbs in white matter in TBI patients. APP accumulations had been 
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demonstrated within axons of the corpus callosum after severe TBI (McCracken, et al., 
1999). In addition, APP immunoreactive axonal swellings were described in the corpus 
callosum, fornices, brainstem, and subcortical white matter in mild TBI patients who died 
of other causes (Blumbergs, et al., 1994). Degeneration and atrophy of the fornices and 
corpus callosum as measured using magnetic resonance imaging have also been 
described (Levin, et al., 1990; Gale, et al., 1993).  
There may be an injury dose response in our model. There was a mean of 82.6 
swellings and bulbs per square mm after 8 mm optic nerve stretch, but only 22.0 after 6 
mm stretch and 1.2 in control nerves. With 3 animals in each group, several of the post-
hoc comparisons were not statistically different. Increasing our sample size may allow us 
to demonstrate statistically different injury dose responses. This may allow for the study 
of therapeutic intervention after mild and severe TAI with our model. 
 
Post-injury hypothermia provides long-term protection after TAI 
Posttraumatic hypothermia had previously been shown to afford short-term 
axonal protection in models of TAI (Koizumi and Povlishock, 1998; Maxwell, et al., 1999; 
Maxwell, et al., 2005). The therapeutic benefit of hypothermia was demonstrated as late 
as 8 hours after guinea pig optic nerve stretch (Maxwell, et al., 2005) and as late as 24 
hours after rat impact head acceleration injury (Koizumi and Povlishock, 1998). Both 
studies quantified APP-labeled axons but it is not known whether anterograde transport 
disruption is reversible or whether all APP-labeled axons must degenerate. In one study, 
Brodhun, et al. reported that early posttraumatic hypothermia was not axonal protective 
in juvenile pigs subjected to fluid percussion injury and hypovolemic hypotension. 
However, based on the graphical presentation of their data, the mean number of APP-
labeled axons in the normothermic injured animals without elevated intracranial pressure 
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(ICP) was more than double that of hypothermic animals (none experienced elevated 
ICP). Therefore, this study may have lacked adequate power to detect a treatment 
effect.  
We are the first to determine that axonal protection seen with short-term 
hypothermia is preserved long-term after accounting for the regionalization of injury after 
optic nerve stretch. We were unable to detect a statistically significant difference in total 
axonal counts 2 weeks post-stretch between normothermic animals and those treated 
with short-duration hypothermia in spite of a mean 17% absolute reduction in axon loss 
with hypothermia. We believe our inability to detect at a statistical difference was due to 
the large intra-group variability in total axonal counts and the relative concentration of 
injury in the optic nerve core. When regional density of myelinated axons was compared, 
post-injury hypothermia reduced axonal loss in the nerve core. 
It is unclear why the central region of the optic nerve is preferentially injured. 
Maxwell, et al. (1999) had earlier reported that β-APP immunolabeling occurred 
exclusively in the central 30% of the guinea pig optic nerve after stretch. Solid 
mechanics dictates that homogenous, isotropic materials have a uniform stress 
distribution under axial loading. However, the optic nerve is neither isotropic nor 
homogenous. Past work showed that the microstructure of the optic nerve leads to 
nonlinear behavior of the structure as it is gradually elongated (Bain, et al., 2003; 
Meaney, 2003). One key parameter in this nonlinear behavior is the gradual 
straightening of the axons during slow extension, which leads to an increase in the 
fraction of axons bearing mechanical load at higher elongations. One possible 
mechanical reason for the differential injury pattern in our study is the change in axonal 
microstructure between the periphery and the core. Future data on the regional changes 
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in the microstructure within the rat optic nerve would clarify if this were a contributing 
factor for this observation. 
It is not clear if TBI preferentially injures larger caliber axons as more recent 
studies have suggested otherwise (Povlishock, 1992). However, different size axons 
appear to respond differently to injury. In the guinea pig optic nerve stretch model, small 
and large axons have different responses 4 hours after injury (Jafari, et al., 1997; Jafari, 
et al., 1998). In small axons, there was an increase in neurofilament number and density 
without detectable changes in microtubules, whereas larger axons experienced 
microtubule loss with either no change or a loss of neurofilament (Jafari, et al., 1997). 
Differential cytoskeletal alterations in different size axons were seen up to 7 days (final 
time point) after guinea pig optic nerve stretch (Maxwell, et al., 2003). From our data, 
optic nerve stretch in the rat resulted in loss of axons regardless of size. Despite an 
overall treatment effect in the optic nerve core with hypothermia, there was no statistical 
difference in the density of axons of different sizes between normothermic and 
hypothermic injured nerves. This may again be due to limited statistical power. Our 
cross-sectional axonal area measurements may have been overestimates as not all 
axons were cut perfectly transversed. In spite of this, the data was robust and appeared 
similar across all four quartiles (Figure 9). 
The mechanism of axonal protection with short-duration immediate hypothermia 
remains to be established. It has been previously demonstrated in animal models of TAI 
that short-duration hypothermia reduced microtubule loss, prevented alteration in 
neurofilament structure, and blunted early calpain activity (Büki, et al., 1999a; Maxwell, 
et al., 1999; Sun, et al., 2002). The mechanism is likely multifactorial, and may also 
include reduction in brain metabolic rate, blockade of excitotoxicity, calcium antagonism, 
and modulation of the inflammatory response (Sahuquillo and Vilalta, 2007). 
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Several studies have demonstrated benefit of mild hypothermia after severe TBI 
in humans (Jiang, et al., 2006; Jiang and Yang, 2007). However, a prospective, 
multicenter, randomized trial did not show improved outcomes in severe TBI patients 
treated with mild hypothermia (Clifton, et al., 2001). In that study, the mean time to target 
temperature was over 8 hours and patient inclusion was based on Glasgow Coma Scale 
score so brain pathology was likely diverse. In animal models, axonal pathology was 
seen within minutes of injury and hypothermia was usually instituted immediately 
(Koizumi and Povlishock, 1998; Büki, et al., 1999a; Maxwell, et al., 1999; Sun, et al., 
2002). Severe TBI in humans often include axonal injury, as well as focal or more diffuse 
hemorrhage, with ischemia and ICP elevations as secondary complications. 
Hypothermia potentially can be modified to target specific pathology. For example, 
hypothermia targeting refractory ICP elevation can be started hours after injury but must 
be prolonged for optimal benefit (Jiang, et al., 2006). In our model, we demonstrated that 
immediate, short-duration hypothermia provided long-term axonal protection. 
 
Summary 
In summary, optic nerve stretch in rats appears to model important phenomena 
that occur after human TBI. Injury and degeneration of the rat optic nerve mimic the 
histopathologic changes seen in CNS white matter tracts after human TBI. We were able 
to demonstrate long-term axonal protection with immediate short-duration hypothermia 
after TAI using this model.  
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Figure 3.1 
 
 
 
Figure 3.1. Scoring of SMI-32 labeled swellings and bulbs. (A) Ten µm thick section 
of an optic nerve from an animal sacrificed 4 days after 8 mm optic nerve stretch. 
(B) Discrete swellings and bulbs were counted if a circle with a diameter of 2.5 µm 
were completely contained within their border. Lime green circles have a diameter of 
2.5 µm. Scale bar = 50 µm. 
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Figure 3.2 
 
 
 
 
 
Figure 3.2. Systematic sampling of optic nerve cross-sections using an electron 
microscope. Coordinates for the most superior (x2,y2) and leftward (x1,y1) points of 
the nerve were established (black dots). The starting point for image capture (red 
dot) was determined using the x1 from the most leftward point and y2 from the most 
superior coordinate. Images were captured every 70 µm across and down from the 
starting point. Disruption of normal architecture is apparent even in this low power 
image of an optic nerve taken from an animal sacrificed 2 weeks after normothermic 
8 mm optic nerve stretch. Scale bar = 100 µm. 
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Figure 3.3 
 
 
 
 
 
 
 
Figure 3.3. Affin transformation of coordinates of electron microscopy images taken from 
an optic nerve. (A) Idealized ellipse overlay on spatial plot of coordinates. (B) Affine 
transformation of original coordinates (open circles). Filled circles represent the scaled 
coordinates. 
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Figure 3.4 
 
 
 
Figure 3.4. Traumatic axonal injury 4 days after optic nerve stretch. SMI-32 
immunolabeling of non-phosphorylated neurofilament in 10 µm thick longitudinal 
sections after 6, 7, and 8 mm optic nerve stretch compared to uninjured (control) optic 
nerve. Images captured at 100x magnification. Scale bar = 50 µm. 
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Figure 3.5 
 
 
 
 
Figure 3.5. Number of swellings and bulbs per square mm in control and injured nerves. 
Every 8th longitudinal section of the optic nerve (10 µm thick) was scored. Three nerves 
in each injury group and the 9 contralateral nerves served as controls. Horizontal bars 
represent means. *p=0.009 relative to their respective contralateral control optic nerves.  
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Figure 3.6 
 
 
 
Figure 3.6. Axonal degeneration 2 weeks after 8 mm optic nerve stretch. Representative 
electron microscopy images taken from the central and peripheral regions of uninjured 
and injured optic nerves. Images captured at 13,900x magnification. Scale bar = 1 µm. 
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Figure 3.7 
 
 
 
 
Figure 3.7. Overall effect of post-injury hypothermia on axonal degeneration. (A) Total 
axonal counts from control and injured optic nerves from 6 normothermic and 6 
hypothermic animals. *p=0.002 when comparing control and injured normothermic 
groups. (B) Percent difference in total axonal counts between the injured optic nerve and 
contralateral control nerve. Horizontal bars represent means. 
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Figure 3.8 
 
 
 
 
Figure 3.8. Regional effect of post-injury hypothermia on axonal degeneration. Axon 
densities from control and injured optic nerves from 6 normothermic and 6 
hypothermic animals. Error bars represent standard deviation. *p<0.0001 relative to 
control normothermia core. **p=0.027 relative to injured normothermia core. 
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Figure 3.9  
 
 
 
Figure 3.9. Injury and hypothermic protection based on axon size. Axons with cross-
sectional areas less than 0.56, between 0.56 and 0.92, between 0.92 and 1.59, and 
greater that 1.59 µm2 are grouped into the first, second, third and fourth quartiles, 
respectively. Quartiles were based on the size distribution of axons in control 
normothermic optic nerves. Error bars represent standard deviation. *p≤0.01 when 
comparing control and injured normothermic animals. 
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CHAPTER 4: 
Short-duration treatment with the calpain inhibitor 
MDL-28170 does not protect axonal transport in 
an in vivo model of traumatic axonal injury 
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ABSTRACT  
Traumatic axonal injury is characterized by early cytoskeletal proteolysis and 
disruption of axonal transport. Calpain inhibition has been shown to protect axons in 
rodent models of traumatic brain injury. However, in these models, both white and gray 
matter are injured making it difficult to determine if calpain inhibitors are directly 
protecting injured axons. To address this issue, we used our rat optic nerve stretch 
model to test the hypothesis that early calpain inhibition directly protects central nervous 
system (CNS) axons following stretch injury. Rats were given an intravenous bolus of 
the calpain inhibitor MDL-28170 (30 mg/kg) 30 minutes prior to unilateral optic nerve 
stretch, followed by a 15 mg/kg/hr intravenous infusion over the next 2.5 hours. 
Immunohistochemical analysis of optic nerves 30 minutes after stretch injury revealed 
variable increases of calpain-cleaved α-spectrin that appeared less evident in stretched 
nerves from drug treated rats, although this difference was not statistically significant. 
Retrograde axonal transport measured by fluorogold labeling of retinal ganglion cells 
was significantly impaired after stretch injury. However, there was no difference in the 
number of fluorogold labeled cells in the vehicle vs. drug treatment groups. These 
results suggest that early short-duration calpain inhibitor therapy with MDL-28170 is not 
an effective strategy to prevent disruption of axonal transport following isolated axonal 
stretch injury in the CNS.  
 
KEYWORDS 
axonal injury; axonal transport; traumatic brain injury; animal studies; adult brain injury
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INTRODUCTION 
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is 
estimated to afflict over 10 million people annually (Hyder et al., 2007). It is predicted by 
the year 2020, road traffic injuries, which are currently the leading cause of TBI, will be 
the third leading cause of death and disability (Murray and Lopez, 1997). Traumatic 
axonal injury (TAI) is thought to be a major contributor to the neurologic dysfunction 
seen after mild TBI, as well as the high morbidity and mortality seen in severe TBI 
patients. 
Implicated in TAI, calpains are a family of Ca2+-dependent nonlysosomal 
proteases involved in cytoskeletal remodeling, cell-cycle regulation, signal transduction, 
apoptosis, and necrosis (Zatz and Starling, 2005). There are two ubiquitous isoforms, 
calpain I and calpain II, which differ in the Ca2+ concentration required for in vitro activity. 
Early calpain activity after trauma is likely caused by reversible Ca2+ overload either due 
to disruption of the axolemma or dysregulation of ionic transport proteins (Iwata et al., 
2004; Wolf et al., 2001). Directly measuring axonal Ca2+ immediately after TAI in vivo is 
particularly challenging. However, isolated stretch of neurites of primary cortical neurons 
resulted in an immediate rise in Ca2+ in injured processes (Iwata et al., 2004; Staal et al., 
2010). Calpain activity has been reported to be elevated within minutes after 
experimental TAI (Büki et al., 1999b; Saatman et al., 2003). In a mouse optic nerve 
stretch model, diffuse calpain activity measured by immunolabeling of calpain-cleaved α-
spectrin (Ab38) was detected 20-30 minutes post-injury (Saatman et al., 2003). This 
signal was typically no longer detectable at 4 hours post-injury. Although a direct 
measure of calpain activity and elevated cytosolic Ca2+, immunoreactivity for calpain-
cleaved α-spectrin also signals cytoskeletal proteolysis and degradation. In addition to α-
spectrin, the neurofilament triplet proteins, tubulin, and tau are known calpain substrates. 
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In both humans and animals, trauma produces a rapid elongation or deformation 
of axons that generally does not cause primary axotomy (immediate tearing of the axon) 
but leads to progressive structural damage culminating in secondary axotomy (Jafari et 
al., 1997; Maxwell and Graham, 1997; Povlishock and Katz, 2005; Povlishock et al., 
1997; Saatman et al., 2003). Impairment of axonal transport with subsequent 
accumulation of transported proteins and organelles, commonly visualized using 
antibodies targeting beta-amyloid precursor protein (ß-APP) or nonphosphorylated 
neurofilament, are hallmarks of TAI. A more direct measure of transport, such as 
retrograde transport of fluorogold after its injection into the superior colliculus, is 
disrupted after optic nerve stretch (Saatman et al., 2003). It is believed that post-
traumatic calpain activity within axons contributes to transport disruption, cytoskeletal 
degradation, and subsequent axotomy. However, there is also robust calpain activity in 
neuronal somata and dendrites after TBI (Saatman et al., 2010). Trying to measure the 
role of axonal calpains in whole brain TBI models is complex because many supra-
axonal structures are affected. In this study, we address this issue by using an in vivo 
optic nerve stretch model, where injury is localized primarily to axons (Ma et al., 2009). 
We have also demonstrated that this model is amenable to therapeutic intervention as 
short-duration post-injury hypothermia reduced axonal degeneration 2 weeks after nerve 
stretch. 
Pharmacologic inhibition of CNS calpain activity in vivo remains challenging, and 
no ideal agent has emerged. However, the cell-permeable MDL-28170 is one of the 
most well studied calpain inhibitor, has high specificity, and ameliorated TAI in global 
brain injury models. A single intravenous (IV) bolus (30 mg/kg) of MDL-28170 has been 
shown to reduce axonal pathology in global head injury models (Ai et al., 2007; Büki et 
al., 2003; Czeiter et al., 2009). It is not known whether pharmacologic protection occurs 
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at the level of the axons, supra-axonal structures or both as the injury model is not 
selective to axons. This may have important clinical implications as certain brain injuries 
may have predominant axonal versus somal/dendritic effects. There are no published 
studies evaluating any calpain inhibitor in the optic nerve stretch model. 
The goal of this study was to determine if a calpain inhibitor strategy targeting 
early pathologic calpain activity would prevent the disruption of axonal transport in a 
model of isolated TAI. Using our established rat optic nerve stretch model, we tested a 
pharmacologic strategy previously shown to protect axons in other models of TBI. We 
hypothesized that early intravenous therapy with the calpain inhibitor MDL-28170 will 
reduce α-spectrin proteolysis and axonal transport disruption after optic nerve stretch. 
These results could have important implications for targeting pathologic calpain activity 
after TBI. 
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MATERIALS AND METHODS 
All animal procedures were performed in accordance with NIH guidelines for the care 
and use of laboratory animals and were approved by our Institutional Animal Care and 
Use Committee. 
 
Rat Optic Nerve Stretch 
Adult male Long-Evans rats (weight 300-400 grams) underwent general 
anesthesia with 2.5% isoflurane and were placed on a heating pad. Anesthesia was 
maintained via a nose cone. A femoral venous catheter was placed by cut-down for drug 
therapy. To receive optic nerve injury, rats were placed in a stereotactic head holder that 
was positioned on the injury device (modified from Gennarelli et al., 1989). The cornea 
was anesthetized with 0.5% proparacaine, and the eye was kept moist at all times using 
sterile saline. The conjunctiva was separated from the sclera using an incision extending 
around the entire circumference of the eye except for the medial aspect (to minimize 
bleeding). A flexible thin ring-shaped plastic sling, which had a continuous loop of 4-0 
monofilament nylon suture secured to it at 4 places 90° apart, was placed behind the 
eye. The sling had a break in its ring so the ends could be spread apart to allow 
placement behind the eye, and, after placement, the two ends of the ring were tied 
together. The monofilament nylon loop was then attached to the optic nerve stretch 
device. 
The head was positioned on the injury device such that the trajectory of the retro-
orbital portion of the optic nerve was aligned with the stroke of the solenoid. The sling 
was connected to a force transducer (LFS 270; Cooper Instruments & Systems, 
Warrenton, VA) mounted in series with a solenoid (Lucas-Ledex, Vandalia, OH). To 
ensure consistent loading, a 12 gram preload, measured by the force transducer, was 
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placed on the nerve. The magnitude of the displacement was controlled by a 
micromanipulator that adjusts the distance traveled by the solenoid piston. The 5.5 mm 
magnitude of optic nerve stretch reported here refers to piston displacement. The 
distance the piston traveled was significantly more than the actual stretch of the optic 
nerve consistent with our past experiments in the guinea pig and rat (Bain and Meaney, 
2000; Ma et al., 2009). Immediately after obtaining the preload, the solenoid was 
triggered to produce a rapid elongation of the nerve. Force measurements were 
captured at 10 kHz using LabVIEW SignalExpress (National Instruments, Austin, TX). 
For 5.5 mm stretch, the nerve was extended to the maximum displacement, held briefly, 
and then returned to its original pre-injury position within 75 ms of initially activating the 
solenoid. The peak displacement occurred within 25 ms after triggering the solenoid, 
which is consistent with the timing of peak deformation that occurs within the brain 
during conditions that cause diffuse axonal injury (Meaney et al., 1995). Peak force 
ranged from approximately 700-1000 grams. Animals were excluded if injury to the globe 
or tearing of the optic nerve was apparent by visual inspection. Approximately 30% of 
optic nerves tore. Twelve animals (6 in each group) were assessed for Ab38 labeling, 
while another 12 (5 in the DMSO group and 7 in the MDL-28170 group) were scored for 
fluorogold transport.  
Rectal temperature was maintained at approximately 36.5–37.5°C at the time of 
injury and then for 2 additional hours. Erythromycin ophthalmic ointment was applied to 
both eyes in all animals, and the lids of the injured eye were sutured together for 2 days 
in animals surviving for 4 days to prevent corneal drying. The contralateral uninjured eye 
and optic nerve were used as controls. Animals sacrificed at 4 days received fluorogold 
injections immediately after optic nerve stretch, while animals perfused 30 minutes after 
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optic nerve stretch for Ab38 immunohistochemistry were kept anesthetized on a heating 
pad until perfusion.  
 
MDL-28170 therapy 
 Prior to injury, a 30 mg/kg bolus of MDL-28170 (50 mg/ml DMSO; Enzo, 
Plymouth Meeting, PA) or equal volume of DMSO vehicle was injected over 10-15 
minutes. Immediately after completion of the bolus, infusion of 15 mg/kg/hr MDL-28170 
or equivalent volume of vehicle was initiated and continued for 2.5 hours. To achieve 
maximum calpain inhibition at time of injury, optic nerve stretch was performed 30 
minutes after completion of the initial IV bolus (Markgraf et al., 1998; Thompson et al., 
2010). 
 
Injection of fluorogold into the superior colliculus 
 To label retinal ganglion cells (RGCs) that were capable of retrograde transport 
after stretch injury, animals received bilateral injections of fluorogold (Fluorochrome, 
Denver, CO) into each superior colliculus. Immediately after optic nerve stretch, a 
midline scalp incision was made and the skull exposed by blunt dissection. Burr holes 
were drilled over each superior colliculus (6.8 mm posterior to bregma, 1.5 mm lateral to 
the sagittal suture). A total of 3 µl of 5% fluorogold was injected over 7.5 minutes at two 
depths (3.5 and 4.3 mm). The scalp was then sutured, and animals were given 0.05 
mg/kg intraperitoneal (IP) buprenorphine prior to recovering. 
 
Immunohistochemistry for calpain cleaved α-spectrin in optic nerves 
Thirty minutes after optic nerve stretch, rats were transcardially perfusion fixed 
with cold 1x PBS followed by cold 4% paraformaldehyde in 0.1 M phosphate buffer. The 
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optic nerves were exposed by dissection, removed from the head and postfixed for 2-3 
hours in 4% paraformaldehyde (4°C). Nerves were subsequently cryoprotected in 30% 
sucrose. The distal 4 mm of both the right and left optic nerves of the same animal were 
frozen in the same OCT block, and were cut longitudinally into 10 µm thick sections on a 
cryostat. Every 10th longitudinal section of the right and left optic nerve in the same 
animal was mounted on the same slide. After drying, slides were pretreated in 0.5% 
H2O2 and 30% methanol for 15 minutes at room temp, rinsed in 1x PBS, and blocked in 
3% goat serum and 0.1% triton x-100. The tissue sections were incubated overnight at 
4oC with Ab38 (1:20,000, kind gift from R. Siman, University of Pennsylvania), which 
reacts with calpain-cleaved α-spectrin. After further PBS rinses, the slides were 
incubated with biotinylated goat anti-rabbit secondary antibody (1:1000; Vector Labs, 
Burlingame, Ca) for 1 hour at room temp. The enzymatic reaction was visualized using 
3, 3’ diaminobenzidine tetrahydrochloride. Slides were rinsed in xylene and coverslipped 
with DPX.  
For semiquantitative assessment of axonal Ab38 labeling, 200x images of the 
region with the most intense Ab38 labeling in every 10th longitudinal section were 
captured by CCD camera attached to a Leica DM4500B (Buffalo Grove, IL). Camera and 
microscope settings were kept constant. The region of greatest Ab38 labeling was 
almost invariably 1 to 2 mm from the chiasm, which is consistent with a study by 
Saatman et al. (2003). The scorer, who was blinded to both treatment and injury, used 
Adobe Photoshop to convert images to grayscale, followed by applying the invert filter so 
more Ab38 staining translated to higher intensity. NIH ImageJ was then used to measure 
the integrated density along a line drawn perpendicular to the long axis of the nerve and 
across the region with the most intense Ab38 labeling. The sum of the integrated density 
from every 10th longitudinal section was divided by the sum of the lengths of the drawn 
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line (width of the nerve sections). The mean value obtained from the uninjured nerve 
was subtracted from the injured side of the same animal. The higher the number, the 
more intense the staining in the injured nerve versus the contralateral uninjured nerve. 
 
Assessment of fluorogold axonal transport in retinal ganglion cells 
Four days after optic nerve stretch, a rats in each group were reanesthetized and 
transcardially perfusion fixed as described above. Retinas were removed from the eye 
and postfixed for 2-3 hours in 4% paraformaldehyde (4°C). After washing with 1x PBS, 
retinal flat mounts were blocked in 10% goat serum, 1% BSA, and 0.2% triton x-100 in 
1x PBS for one hr at room temp. Retinas were incubated overnight at 4oC with TUJ1 
(1:1000; Covance, Princeton, NJ), which labels RGCs. After further washes, retinas 
were incubated in alexa 488 goat anti-mouse (1:1000; Molecular Probes, Eugene, OR) 
overnight at 4oC. Retinas were washed and coverslipped with fluoromount.  
After TUJ1 immunohistochemistry, the retina was flat mounted and viewed with a 
fluorescent microscope (Leica DM4500B). Fluorogold was imaged using the A4 filter 
cube. Images of labeled RGCs were taken in black and white (and subsequently 
colorized) at 200x mag in 12 standard fields—1/6, 3/6 and 5/6 of the retinal radius from 
the center of the retina in each quadrant. FG-positive RGCs were counted by a blinded 
observer using Adobe Photoshop and NIH ImageJ. 
 
Statistical Analysis 
The Ab38 signal intensities in the DMSO and MDL-28170 groups were compared 
using the Student’s t-test. To compare fluorogold counts, analysis of variance in 
repeated measures was performed. A p-value < 0.05 for main effects and <0.2 for the 
interaction space were considered statistically significant. Pairwise comparisons were 
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specified a priori and were accomplished using the t-test with pooling of the variance. 
Significance levels for pairwise comparisons were adjusted for by using the Bonferroni 
correction. There were two pre-planned comparisons: injured versus uninjured retinas in 
DMSO-treated animals, and DMSO versus MDL-28170 injured retinas. For these 2 
pairwise comparisons, a p<0.025 was considered significant. Data are presented as 
means and standard deviations. All data were analyzed using SAS statistical software 
(version 9.2, SAS Institute, Cary, NC). 
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RESULTS 
Effect of MDL-28170 administration on calpain-mediated α-spectrin degradation 
Thirty minutes after optic nerve stretch, the most intense Ab38 labeling was seen 
1-2 mm from the optic chiasm (Fig. 1). In this region of intense signal, it was difficult to 
identify individual Ab38 labeled axons, whose diameters are approximately 1 µm, in a 10 
µm thick section. Ab38 signal was not seen in the contralateral unstretched nerve.  
Based on semiquantitative analysis, injured nerves from animals treated with 
DMSO have variable amounts of Ab38 labeling 30 minutes after injury relative to 
contralateral uninjured controls (intensity difference = 7.6±10.7). In contrast, Ab38 
labeling in injured nerves from MDL-28170 treated rats was similar to the contralateral 
nerve in all cases (intensity difference = -0.2±2.2). However the mean intensity of 
staining was not statistically different between treatment groups (p=0.11). 
 
Fluorogold positive cells in the retina 
 As a functional outcome, we wanted to determine if the disruption of retrograde 
transport after optic nerve stretch could be ameliorated with calpain inhibition. Transport 
of fluorogold injected into the superior colliculus has been previously reported to be 
impaired after optic nerve stretch in mice (Saatman et al., 2003). In our model, there was 
a significant INJURY effect (p<0.0001) but not a TREATMENT effect (MDL-28170 
versus DMSO, p=0.74) nor interaction (INJURY*TREATMENT, p=0.87). We detected a 
significant decrease in the number of fluorogold labeled RGCs after optic nerve stretch 
in animals administered DMSO, indicating disruption of retrograde axonal transport 
(p=0.002; Fig. 2). However, preinjury short-duration MDL-28170 therapy was not 
protective relative to DMSO injured retinas (p=0.93). The percentage decrease in FG 
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labeled RGCs after optic nerve stretch (comparing injured to its contralateral uninjured 
nerve) was 66±30% in DMSO treated rats versus 64±25% in MDL-28170 treated rats. 
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DISCUSSION 
Overall, we were unable to demonstrate statistically significant inhibition of early 
post-injury calpain activity or long-term protection of axonal transport with intravenous 
MDL-28170 pretreatment in our rat optic nerve stretch injury model. Unlike the effects 
demonstrated in other models of traumatic brain injury, our results suggest that early 
calpain inhibitor therapy with MDL-28170 might have limited potential in directly 
preventing disruption of axonal transport caused by isolated axonal stretch injury. 
 
Calpain inhibition in TBI  
Intravenous MDL-28170 has been demonstrated to penetrate into the 
parenchyma of uninjured brains as well as having neuroprotective properties after 
ischemic and traumatic brain injury (Markgraf et al., 1998; Thompson et al., 2010). The 
blood-optic nerve barrier is similar in structure to the blood-brain barrier (Zhao et al., 
2007). A single 30 mg/kg IV dose of MDL-28170 30 minutes prior to impact head 
acceleration injury in rats reduced ß-APP and RMO-14 staining in the corticospinal tract 
and medial longitudinal fasciculus 2 hours post-injury (Büki et al., 2003). RMO-14 is 
believed to indicate pathologic proteolysis or dephosphorylation of neurofilament 
sidearms. Czeiter et al. (2009) subsequently used the same dosing strategy, which 
resulted in improved axolemmal integrity in the corticospinal tract 2 hours post-impact 
head acceleration injury. Longer-term protection was also achieved with a single 30 
mg/kg IV dose of MDL-28170. Given 30 minutes prior to fluid percussion injury in rats, 
there was preservation of compound action potential and decreased ß-APP labeling of 
corpus callosum up to 7 days after injury (Ai et al., 2007). 
Trying to tease apart the role of axonal calpains in in vivo whole brain TBI models 
is complex as the traumatic event may proximately damage nuclei, dendritic fields, nerve 
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tracts, glia, and vasculature (Ma et al., 2009). The interplay between the various brain 
structures does not allow the investigator to isolate the specific mechanism of TAI. Direct 
injury to neuronal cell bodies and their dendritic fields, glial cells, or vasculature, as well 
as elevated intracranial pressure and secondary ischemia, could have secondary effects 
on axons. These limitations can be significantly overcome in the optic nerve stretch 
model. The optic nerve shares similar properties with white matter tracts within the brain, 
including poor regenerative capacity, myelin sheath structure, and the presence of 
oligodendrocytes (Cho et al., 2005; Hirano and Lena, 1995). 
 
Axonal transport disruption after optic nerve stretch 
The characteristics of axonal injury and degeneration seen after optic nerve 
stretch mimic those found in established whole brain models of axonal injury, as well as 
in human brain after TBI (Ma et al., 2009). Axonal swellings and bulbs are hallmarks of 
TAI, and are thought to result from primary axonal transport disruption. In a murine optic 
nerve stretch model, approximately 60% of axons failed to transport fluorogold from the 
superior colliculus (Saatman et al., 2003). Retrograde axonal transport of fluorogold was 
also impaired after experimental closed head injury in mice (Creed et al., 2011). 
We were unable to show an improvement of retrograde axonal transport of 
fluorogold after unilateral optic nerve stretch in animals given MDL-28170. Maxwell and 
Graham (1997) demonstrated in the guinea pig optic nerve stretch model that there was 
a dramatic loss of microtubules throughout axons 15 minutes post-injury. As 
microtubules are known calpain substrates, an attractive hypothesis is that calpains 
proteolyze microtubules, resulting in transport disruption. Our short-duration intense 
therapy was targeted toward these early events. It may be necessary to inhibit calpains 
for a longer duration.  
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Limitations 
We attempted to maximize the total dose of MDL-28170 by giving a 30 mg/kg 
bolus followed by 15 mg/kg/hr infusion for 2.5 hrs. However, it is possible that the 
resulting MDL-28170 concentration in the optic nerve axons was not sufficient to inhibit 
pathologic calpain activity. Based on available evidence, we do not believe a higher 
dose would be feasible in our model. During the initial MDL-28170 bolus, approximately 
15-20% of rats had transient bradycardia and respiratory difficulty, and deaths occurred 
when we tried to increase the infusion rate. These adverse effects were not seen when 
DMSO was administered alone. In rabbits, a 60 mg/kg IV infusion of MDL-28170 over 10 
minutes has been reported to be lethal (Neumar et al., 1998). MDL-28170 doses higher 
than 30 mg/kg IP were lethal in mice. (Üçeyler et al., 2010). 
The results of this study do not demonstrate a statistically significant decrease of 
Ab38 labeling 30 minutes after optic nerve stretch in animals treated with MDL-28170 
versus DMSO alone. However, half of the animals in the DMSO group had high Ab38 
intensity in the stretched nerve, whereas all the animals in the MDL-28170 group had 
similar intensity in the stretched and contralateral uninjured nerve. The variability of 
pathologic calpain activity in the DMSO group highlights a limitation of the model, which 
makes it more difficult to find a statistically significant treatment effect. 
 
Conclusions 
There is growing evidence that inhibiting calpains in experimental TBI models 
protects against axonal pathology. However, it is not known where in the neuron these 
inhibitors exert their effects. We attempted to address this question by using a well-
studied calpain inhibitor in an in vivo model of isolated axonal stretch injury. Using this 
model, we were not able to detect a therapeutic benefit of short duration intravenous 
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MDL-28170 therapy. It is believed that after mild TBI, long white matter tracts are 
preferentially injured, and this loss of “connectivity” may underlie the persistent 
symptoms seen in this group of patients. Axonal injury is offered as an explanation as to 
why some patients after trauma are comatose even when their brains lack mass lesions 
(Gennarelli et al., 1982). Therefore, continued work is needed to determine if 
mechanisms of axonal degeneration differ between isolated white matter injury and 
predominantly gray matter or mixed injury. If significant differences exist, then it might be 
necessary to individualize therapeutic strategies to target the appropriate injury pathway.
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Fig. 4.1. Effect of intravenous MDL-28170 on calpain-mediated α-spectrin degradation 
30 minutes after optic nerve stretch. (A) Ab38 immunolabeling for calpain-cleaved α-
spectrin proteolytic fragments in 10 µm thick longitudinal sections of optic nerves. 
Animals received MDL-28170 or DMSO vehicle alone prior to unilateral optic nerve 
stretch. Images near the optic chiasm were captured at 400x magnification. Arrows 
highlight discrete Ab38 labeled axonal profiles in an animal treated with MDL-28170, 
whereas in regions of intense Ab38 labeling in DMSO animals, labeling is more diffuse. 
Scale bar = 20 µm. (b) Semiquantitative assessment of Ab38 staining intensity. 
Horizontal bar represents the group mean. 
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Figure 4.2. 
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Fig. 4.2. Effect of intravenous MDL-28170 on axonal transport disruption 4 days after 
optic nerve stretch. (A) Representative images captured at 200x of retinal flat mounts 
immunolabeled for tuj1 antibody (neuron-specific class III β-tubulin), a marker of RGCs 
(green). Fluorogold is pseudocolored red. Animals received MDL-28170 or DMSO 
vehicle alone prior to unilateral optic nerve stretch and fluorogold injection. Scale bar = 
50 µm. (B) Quantification of RGCs that were able to transport fluorogold from the 
superior colliculus after unilateral optic nerve stretch. Horizontal bar represents the 
group mean. *p=0.002 when comparing uninjured and injured DMSO retinas. 
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CHAPTER 5: 
Calpastatin overexpression protects axonal 
transport in an in vivo model of traumatic axonal 
injury 
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ABSTRACT  
Traumatic brain injury (TBI) causes substantial morbidity and mortality worldwide. 
A key component of both mild and severe TBI is diffuse axonal injury. Except in cases of 
extreme mechanical strain, when axons are torn at the moment of trauma, axonal stretch 
injury is characterized by early cytoskeletal proteolysis, transport disruption, and 
secondary axotomy. Calpains, a family of Ca2+-dependent proteases, have been 
implicated in this pathologic cascade, but direct in vivo evidence is lacking. To test the 
hypothesis that calpains play a causal role in axonal stretch injury in vivo, we used our 
rat optic nerve stretch model following adeno-associated viral (AAV) vector mediated 
overexpresssion of the endogenous calpain inhibitor, calpastatin, in optic nerve axons. 
AAV vectors were designed for optimal expression of human calpastatin 
(hCAST) in retinal ganglion cells (RGCs). Calpain inhibition by the overexpressed 
transgene was then confirmed in primary cortical cultures. Finally, we performed bilateral 
intravitreal injections of AAV vectors expressing hCAST or the reporter protein ZsGreen 
3 weeks prior to unilateral optic nerve stretch. Immediately after stretch injury, fluorogold 
was injected into the superior colliculi for assessment of retrograde axonal transport. 
Rats were euthanized 4 days after stretch injury. Both hCAST and ZsGreen were 
detected in axons throughout the optic nerve to the chiasm. Calpastatin overexpression 
partially preserved axonal transport after stretch injury (58.3±15.6% reduction in 
fluorogold labeling relative to uninjured contralateral control in ZsGreen expressing 
RGCs versus 33.8±23.9% in hCAST expressing RGCs; p=0.038). These results provide 
direct evidence that calpains within axons play a causal role in transport disruption after 
in vivo stretch injury.  
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HIGHLIGHTS 
(1) Viral vector mediated transduction of retinal ganglion cells in combination with the 
optic nerve stretch model is a promising tool to explore the molecular mechanisms of 
axonal stretch injury in vivo. 
(2) In vivo optic nerve stretch results in axonal swellings and bulbs and retrograde 
transport disruption. 
(3) Calpain inhibition within axons protects retrograde axonal transport after isolated 
axonal stretch injury in vivo.  
 
KEYWORDS 
adeno-associated viral vectors; axonal injury; axonal transport; calpains; calpastatin; 
traumatic brain injury 
 
ABBREVIATIONS 
AAV, adeno-associated viral/virus; APP, amyloid precursor protein; CAST, calpastatin; 
DAPI, 4,6-diamidino-2-phenylindole; DIV, days in vitro; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; HRP, horseradish peroxidase; hCAST, human calpastatin; 
IV, intravenous; NFH, neurofilament heavy subunit; RGC, retinal ganglion cell; TAI, 
traumatic axonal injury; TBI, traumatic brain injury 
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INTRODUCTION 
Worldwide, traumatic brain injury (TBI) leading to death or hospitalization is 
estimated to afflict over 10 million people annually, and is predicted to surpass many 
diseases as the major cause of death and disability by the year 2020 (Hyder et al., 
2007). Traumatic axonal injury (TAI) is implicated in the cognitive dysfunction seen after 
mild TBI, as well as coma and mortality after severe TBI (Gennarelli et al., 1982; 
Medana and Esiri, 2003). Blunt brain trauma produces a rapid elongation or deformation 
of axons that may lead to progressive axolemmal and cytoskeletal damage culminating 
in secondary axotomy (Jafari et al., 1997; Maxwell and Graham, 1997; Povlishock and 
Katz, 2005; Povlishock et al., 1997; Saatman, et al., 2003). Mechanical deformation of 
axons results in focal impairment of axonal transport with subsequent accumulation of 
transported proteins and organelles. Accumulations of amyloid precursor protein (APP), 
which undergoes fast anterograde transport, are seen as early as 2 hours after TBI in 
humans (Blumbergs et al., 1995; McKenzie et al., 1996). Anterograde transport of 
intravitreally injected horseradish peroxidase (HRP) and retrograde transport of 
fluorogold after its injection into the superior colliculi, are both disrupted after optic nerve 
stretch, an in vivo model that isolates mechanical strain primarily to axons (Gennarelli et 
al., 1989; Ma et al., 2012; Saatman et al., 2003). Similarly, HRP accumulations are also 
seen in a more diffuse brain injury model, fluid percussion injury in cats (Povlishock et 
al., 1983). 
Post-traumatic calpain activity within axons has been proposed to contribute to 
cytoskeletal degradation, neurofilament compaction, and transport disruption (Büki and 
Povlishock, 2006; Büki et al., 2003; Saatman et al., 2010). Calpains are a family of 
nonlysosomal Ca2+-dependent proteases involved in cytoskeletal remodeling, signal 
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transduction, apoptosis, and necrosis (Zatz and Starling, 2005). The two ubiquitous 
calpains, µ- and m-calpain, are heterodimeric peptides, consisting of different catalytic 
isoforms and a common regulatory subunit. They differ in the Ca2+ concentration 
required for in vitro activity. The family also consists of calpastatin (CAST), an 
endogenous inhibitor of both µ- and m-calpain that does not inhibit proteases in any 
other family (Goll et al., 2003). Calpain activity measured by immunolabeling for calpain-
cleaved α-spectrin (Ab38) is observed in axons in the pyramidal tracts and medial 
lemnisci 15 minutes after head acceleration injury in rats (Büki et al., 1999b). Early 
axonal calpain activity after fluid percussion injury has been reported (Saatman et al., 
1996). After optic nerve stretch, elevated calpain activity is detectable 20-30 minutes 
post-injury (Ma et al., 2012; Saatman et al., 2003).   
Pharmacologic inhibition of central nervous system calpain activity remains 
challenging, and there is no pharmacologic inhibitor completely specific for calpains (Goll 
et al., 2003). Nevertheless, various calpain inhibitors have demonstrated neuroprotection 
in diffuse TBI models (Saatman et al., 2010). MDL-28170 is perhaps the most well 
studied calpain inhibitor. Even though specific for calpains, it also has significant activity 
against cathepsin B (Markgraf et al., 1998). A single intravenous (IV) bolus (30 mg/kg) of 
MDL-28170 reduces axonal pathology in rodent TBI models (Ai et al., 2007; Büki et al., 
2003; Czeiter et al., 2009). In contrast, in the optic nerve stretch model, intensive MDL-
28170 therapy does not protect retrograde transport of fluorogold (Ma et al., 2012). It is 
not known whether pharmacologic protection seen in the diffuse TBI models occurs at 
the level of the axons, supra-axonal structures or both as neither the injury nor therapy is 
selective to axons.  
In contrast to pharmacologic inhibitors, calpastatin is completely specific for 
calpains (Goll et al., 2003). Calpastatin overexpression has been used to protect 
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hippocampal neurons after kainite injection (Higuchi et al., 2005; Rao et al., 2008; 
Takano et al., 2005) and transient global ischemia (Cao et al., 2007). Our strategy was 
to overexpress calpastatin in retinal ganglion cell (RGC) axons prior to optic nerve 
stretch. We hypothesized that calpastatin overexpression within axons would protect 
retrograde transport. Determining the specific role of calpains in isolated axonal injury 
may have important implications for targeting pathologic calpain activity after TBI and 
spinal cord injury.  
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MATERIALS AND METHODS 
All animal procedures were performed in accordance with National Institutes of 
Health guidelines for the care and use of laboratory animals and were approved by our 
Institutional Animal Care and Use Committee. All appropriate bio-safety procedures 
were followed in handling the adeno-associated viral (AAV) vectors. 
 
Viral vector generation 
 Cloning and generating the recombinant AAV vectors (serotype 2) were 
performed by the Vector Core at the University of Pennsylvania. The human calpastatin 
(hCAST; clone ID 3878564 from Open Biosystems, Huntsville, AL) or ZsGreen gene 
(Clontech, Mountain View, CA) was cloned into pENN.AAV.CB7, an AAV packaging 
plasmid, downstream of the CB7 promoter. CB7 is a chicken ß-actin promoter with 
cytomegalovirus enhancer elements. The viral genomes encoded in both constructs 
were verified by sequencing analysis prior to vector production. Generation of the AAV 
vectors has been previously described (Gao et al., 2002). 
 
Primary cortical neuron culture 
 Cortices from E17-19 Sprague-Dawley rat embryos were trypsinized in 
DMEM (BioWhittaker-Lonza, Basel, Switzerland) containing 0.027% trypsin for 15 min. 
They were triturated in media consisting of DMEM supplemented with 10% fetal calf 
serum (Hyclone, Logan, UT). Dissociated cells were plated at a density of ~260 
cells/mm2 in 24 well plates with glass coverslips or ~620 cells/mm2 in 35-mm dishes. 
Dishes and coverslips were coated with poly-L-lysine (Peptides International, Louisville, 
KY). Cultures were maintained in serum-free Neurobasal medium (Life Tech., Grand 
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Island, NY) supplemented by B27 (Life Tech.) in a humidified 5% CO2 incubator at 37ºC. 
Mitotic inhibitors and antibiotics were not used. 
 
AAV vector testing in primary cortical neuron culture 
Neuronal cultures 7 days in vitro (DIV) were transduced with 6 x 109 (24 well 
plate) or 3.3 x 1010 genome copies (35-mm dish) of AAV vectors expressing either 
ZsGreen (AAV.ZsGreen) or hCAST (AAV.hCAST). Fourteen days later, cultures were 
fixed with 4% paraformaldehyde, immunolabeled for hCAST (MAB3084; 1:4000; 
Millipore, Billerica, MA), and counter-stained with 4,6-diamidino-2-phenylindole (DAPI) 
nuclear label. MAB3084 detects human, but not rat, CAST. Additional cultures were 
harvested and sonicated in homogenization buffer (25 mM HEPES, ph 7.4, 1 mM EDTA, 
0.1% CHAPS). Protein concentration was quantified using the Bradford assay. Proteins 
were separated by SDS-PAGE on a 4-20% tris-glycine gel, transferred to a nitrocellulose 
membrane, and probed for hCAST (MAB3084; 1:1000) and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; PA1-988; 1:1000; Thermo Scientific, Rockford, IL). Blots were 
visualized using enhanced chemiluminescence. HRP-conjugated secondary antibodies 
and enhanced chemiluminescence substrate were purchased from Perkin Elmer 
(Waltham, MA). 
Functional hCAST overexpression was assessed by measuring calpastatin 
activity in transduced and nontransduced cell extracts. Cultures (3-5 per condition) were 
harvested as described above. Protein concentrations of the cell extracts were adjusted 
to 3 µg/µl. Extracts were heated to 90ºC for 5 min then centrifuged at 16,000 g at 4ºC for 
20 min. Reactions contained 5 µl of supernatant, 10 nM human erythrocyte calpain 1 
(EMD, Gibbstown, NJ), 200 µM Suc-Leu-Tyr-MNA (MP Biomedicals, Solon, OH), and 
195 µl of the homogenization buffer with 5 mM B-mercaptoethanol. The reaction 
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performed at room temp, was started by adding CaCl2 to a final concentration of 5 mM. 
Time-dependent substrate proteolysis, which results in increasing fluorescence, was 
measured on a microplate reader (Turner Biosystems, Sunnyvale, CA; 365 nm 
excitation, 410-460 nm emission). All samples were assayed in triplicate. 
 
Intravitreal injection of AAV vectors 
Adult male Long-Evans rats (130-160 g) underwent isoflurane anesthesia 
followed by application of 0.5% proparacaine eyedrops. Using an operating microscope 
(Zeiss Opmi MD, Thornwood, NY), a superotemporal conjunctival incision was made to 
expose the sclera posterior to the lens. A pilot hole was made with a 30 gauge needle 
followed by the introduction of the tip of a glass micropipette containing the viral vector. 
The micropipette was connected to a 5 µl glass syringe by polyethylene tubing filled with 
mineral oil. Both eyes in the same animal were injected with the same vector (4 µl at a 
concentration of 1.13 x 1012 genome copies/ml).  
 
Optic nerve stretch 
One blinded investigator performed all surgeries. In each operative day, 
approximately half of the rats were transduced with either AAV.hCAST or AAV.ZsGreen. 
Three weeks after intravitreal injection, rats underwent unilateral optic nerve stretch as 
described previously (Ma et al., 2012). In brief, rats were anesthetized with isoflurane 
and placed in a stereotactic head holder that was positioned on the injury device. Body 
temperature was maintained at ~37.5ºC and pulse ox between 94-98%. A flexible thin 
ring-shaped plastic sling, which had a continuous loop of 4-0 monofilament nylon suture 
secured to it at 4 places 90° apart, was placed behind the eye. The monofilament nylon 
loop was then attached to the optic nerve stretch device. To ensure consistent loading, a 
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12 gram preload, measured by a force transducer (LFS 270; Cooper Instruments & 
Systems, Warrenton, VA), was placed on the nerve. The magnitude of the displacement 
was controlled by a micromanipulator that adjusts the distance traveled by the solenoid 
piston. The 5.5 mm magnitude of optic nerve stretch reported here refers to piston 
displacement. The distance the piston traveled was significantly more than the actual 
stretch of the optic nerve (Bain and Meaney, 2000; Ma et al., 2009). Immediately after 
obtaining the preload, the solenoid was triggered to produce a rapid elongation of the 
nerve. Two animals were excluded as the optic nerves tore, leaving 7 Zsgreen and 8 
hCAST rats for analysis. 
After injury, erythromycin ophthalmic ointment was applied to both eyes, and the 
lids of the injured side were sutured together for 2 days to prevent corneal drying. The 
contralateral uninjured eye and optic nerve were used as controls. Animals received 
fluorogold injections immediately after optic nerve stretch.  
 
Assessment of fluorogold labeling of RGCs 
To label RGCs that were capable of retrograde transport, animals received 
bilateral injections of fluorogold (Fluorochrome, Denver, CO) into each superior colliculus 
as previously described (Ma et al., 2012). Four days later, rats were reanesthetized and 
transcardially perfusion fixed with cold 1x PBS followed by cold 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.4). Retinas were removed from the eye and postfixed for 
2-3 hours in 4% paraformaldehyde (4°C). After washing with 1x PBS, retinal flat mounts 
were blocked in 10% goat serum, 1% BSA, and 0.2% triton x-100 in 1x PBS for 1 hr at 
room temp. Retinas were incubated overnight at 4°C with an antibody directed against 
neuronal class III ß-tubulin (1:5000; PRB-435P; Covance, Emeryville, CA), which labels 
RGCs (Cui et al., 2003), and/or MAB3084 (1:4000). After further washes, retinas were 
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incubated in alexa secondary antibodies (Molecular Probes, Eugene, OR) for 2 hours at 
room temp. Retinas were washed and coverslipped with Fluoromount G (Electron 
Microscopy Sciences, Hatfield, PA). 
The retinas were flat mounted and viewed with a fluorescent microscope (Leica 
DM4500B; Buffalo Grove, IL). Camera and microscope settings for fluorogold were kept 
constant across all retinas. Images were taken at 400x mag in 3 areas—1/6, 3/6 and 5/6 
of the retinal radius from the center of the retina—in the region with the highest AAV 
transduction. The “levels” tool in Adobe Photoshop was used in a standardized way to 
increase hCAST and fluorogold contrast and brightness. The black and white levels 
sliders were adjusted to outside the image histogram so the histogram was extended to 
fill the entire tonal range. Scoring was performed by a blinded observer using Adobe 
Photoshop and National Institutes of Health ImageJ. Approximately 30-35 transduced 
RGCs per retinal area were scored for fluorogold. The percentages determined for the 
central, middle and peripheral areas were averaged, and that number is reported here. 
Preliminary work suggested that a smaller percentage of hCAST expressing RGCs 
labeled with fluorogold compared to ZsGreen expressing RGCs (data not shown). To 
control for this potential baseline difference, we decided a priori to compare the 
percentage loss of fluorogold labeling of transduced RGCs as compared to its 
contralateral uninjured side.  
 
Assessment of RGC counts after viral transduction and optic nerve stretch 
To assess RGC counts 4 days after optic nerve stretch, immunolableled retinas 
were divided into thirds and images were taken at 200x mag in 3 areas—1/6, 3/6 and 5/6 
of the retinal radius from the center of the retina—in each of the 3 regions. Two of the 3 
regions were randomly selected, and RGCs (PRB-435P positive cells) were counted by 
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a blinded observer. RGCs obscured by axonal fascicles were not counted. The counts 
from the 6 images were summed and reported here. The total area of the retina scored 
was 1.1 mm2. 
 
Immunohistochemistry of optic nerves 
After perfusion fixation, the optic nerves were removed from the head and 
postfixed for 2-3 hours in 4% paraformaldehyde (4°C). Nerves were subsequently 
cryoprotected in 30% sucrose. The right and left optic nerves of the same animal were 
frozen in the same OCT block, and were cut longitudinally into 14 µm thick sections on a 
cryostat.  
After drying, slides were blocked in 3% goat serum and 0.1% triton x-100 in 1x 
PBS (pH 7.2). The tissue sections were incubated overnight at 4°C with MAB3084 
(1:1000), sc-20779 (detects both rat and human CAST; 1:250; Santa Cruz Biotech., 
Santa Cruz, CA), and/or SMI-32 (1:1000; Sternberger Monoclonals, Lutherville, MD). 
SMI-32 reacts with a non-phosphorylated epitope on neurofilament heavy subunit (NFH). 
Neurofilament accumulation within axons highlights swellings and bulbs (Ma et al., 2009; 
Saatman et al., 2003). After further PBS rinses, the slides were incubated with alexa 
secondary antibodies for 1 hour at room temp. Slides were rinsed and coverslipped with 
Fluoromount G.  
 
Harvesting of optic nerve homogenates for western blot 
Three weeks after intravitreal injection of viral vectors, rats were anesthetized 
with isoflurane and decapitated. The optic nerves were homogenized in 50 mM tris, 150 
mM NaCl, 1% triton, and 2 mM EGTA (pH 7.0) with protease inhibitors (Roche, 
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Indianapolis, IN). Western blot for hCAST and GAPDH was performed as described 
above. 
 
Statistical Analysis 
One-way ANOVA was performed to compare the slopes (fluorescence over time) 
generated by calpain proteolysis of the fluorogenic substrate. Pairwise comparisons 
within the interaction space were specified a priori and were accomplished using the t-
test and appropriate pooled variance. There were 3 pre-planned comparisons: ZsGreen 
versus nontransduced cultures, hCAST versus ZsGreen cultures, and hCAST versus 
nontransduced cultures. To adjust for 3 pairwise comparisons the p-value was set at 
0.017 for statistical significance. The percentage loss of fluorogold labeling in ZsGreen 
and hCAST transduced RGCs after optic nerve stretch were compared using Student’s 
t-test. A p-value < 0.05 was considered statistically significant. ANOVA in repeated 
measures was used for all other analyses. A p-value < 0.05 for main effects and <0.2 for 
the interaction space were considered statistically significant. For the fluorogold labeling 
experiment, there were 4 pre-planned comparisons: ZsGreen versus hCAST uninjured, 
ZsGreen injured versus uninjured, hCAST injured versus uninjured, and ZsGreen versus 
hCAST injured. For 4 pairwise comparisons a p<0.013 was considered significant. Data 
are presented as means and standard deviations. All data were analyzed using SAS 
statistical software (version 9.2, SAS Institute, Cary, NC).  
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RESULTS 
Expression of functional hCAST in primary cortical cultures 
AAV vectors were generated to express hCAST or the fluorescent marker protein 
ZsGreen and initially characterized in primary cortical neuronal cultures. Cultures were 
transduced at 7 DIV. Nontransduced cultures served as controls. At 21 DIV, the cultures 
were analyzed by immunohistochemistry, Western blot, and CAST activity assay. Two 
weeks after AAV vector transduction, there was robust expression of ZsGreen and 
hCAST (Fig. 1). To determine if hCAST was functional, we used a fluorogenic substrate 
microplate assay (Fig. 1B). Proteolysis of Suc-Leu-Tyr-MNA resulted in increasing 
fluorescent signal. ZsGreen cultures were not significantly different than nontransduced 
ones (slopes 17.9±0.7 versus 18.6±0.4, respectively; p=0.15). Lysates from hCAST 
cultures robustly inhibited exogenous calpain activity as compared to ZsGreen and 
nontransduced cultures (slope for hCAST: 1.0±0.7; p<0.0001). Omitting exogenous 
calpain, fluorogenic substrate or CaCl2 resulted in no change in fluorescence (data not 
shown). These results demonstrated that our AAV vectors effectively transduced primary 
cortical cultures resulting in expression of functional hCAST or ZsGreen. 
 
Expression of hCAST and ZsGreen in RGC somata and axons 
After in vivo rat optic nerve stretch, the highest levels of early calpain activity as 
well as the greatest density of swellings and bulbs occurred near the optic chiasm (Ma et 
al., 2012, 2009). Therefore, we confirmed that overexpressed hCAST in RGCs 
undergoes anterograde axonal transport to the prechiasmatic optic nerve. 
Three weeks after intravitreal injection of AAV.ZsGreen or AAV.hCAST, rats 
were sacrificed for immunolabeling of the retina and prechiasmatic optic nerve, as well 
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as immunoblotting of the optic nerve. ZsGreen and hCAST were detected in RGC 
somata, as well as axons near the optic chiasm (Fig. 2). Immunoblotting confirmed 
hCAST in optic nerves (Fig. 2B). 
 
Rat optic nerve stretch results in axonal swellings and bulbs  
Four days after unilateral optic nerve stretch, there were axonal accumulations of 
ZsGreen and hCAST that morphologically appeared to be swellings and bulbs (Fig. 3). 
There appeared to be significantly more ZsGreen accumulations than hCAST, however 
this difference was not quantified (see limitations). Neither type of accumulation was 
present in the contralateral uninjured optic nerves. We immunolabeled optic nerve 
sections with SMI-32, a classic marker of swellings and bulbs. A subset of ZsGreen and 
hCAST accumulations also labeled with SMI-32 (Fig. 3). 
 
Human CAST ameliorates retrograde axonal transport disruption after optic nerve 
stretch 
Axonal stretch injury results in focal disruptions of transport presumably at sites 
of axonal swellings. Therefore, our goal was to inhibit local calpain activity within axons 
by hCAST overexpression, and examine the effect on axonal transport disruption after 
stretch injury. Three weeks after intravitreal injection of AAV vectors in both eyes, 
unilateral optic nerve stretch was performed. This was immediately followed by injection 
of fluorogold into the bilateral superior colliculi. Retinal ganglion cells with intact 
retrograde axonal transport accumulated fluorogold in their somata. Quantification of 
RGCs revealed no evidence of RGC loss 4 days after optic nerve stretch regardless of 
vector treatment (p=0.55; Fig. 4A and 4B).  
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To determine the effect of hCAST expression on axonal transport after stretch 
injury, we quantified the percentage of transduced RGCs (ZsGreen+ or hCAST+) that 
labeled with fluorogold. On the uninjured side, 69.4±9.6% and 57.2±11.5% of ZsGreen+ 
and hCAST+ RGCs, respectively, had fluorogold labeling (p=0.02; Fig. 4C). This result is 
consistent with our preliminary work that suggests decreased fluorogold labeling of 
hCAST transduced RGCs. After stretch injury, 28.3±9.2% of ZsGreen+ RGCs labeled 
with fluorogold (p<0.0001 versus uninjured contralateral retina) while 37.7±12.9% of 
hCAST+ RGCs labeled with fluorogold (p=0.001 versus uninjured contralateral retina). 
This difference in the absolute percentage of ZsGreen+ versus hCAST+ RGCs that label 
with fluorogold after optic nerve stretch was not statistically significant (p=0.07). 
However, when quantified relative to fluorogold labeling of transduced RGCs in the 
uninjured contralateral retinas, optic nerve stretch caused a 58.3±15.6% reduction in 
fluorogold labeling of ZsGreen+ RGCs versus a 33.8±23.9% in hCAST+ RGCs 
(p=0.038; Fig. 4D). This statistically significant difference supports our hypothesis that 
calpains are causally responsible for transport disruption after mechanical stretch of 
axons. 
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DISCUSSION 
We were able to demonstrate statistically significant protection of retrograde 
axonal transport after isolated axonal stretch injury with overexpression of the 
endogenous calpain inhibitor calpastatin. Our current results extend earlier studies that 
demonstrated axonal protection with pharmacologic calpain inhibitors, but were limited 
by potential off target effects and the use of TBI models with mixed gray and white 
matter injury. 
 
Viral vector strategy to study axonal injury mechanisms in vivo 
Pharmacology as a strategy to modulate the molecular mechanisms of neuronal 
and axonal injury after trauma has potentially significant limitations, such as limited 
blood-brain barrier penetration, poor molecular target specificity, and drug toxicity. The 
viral vector approach offers several theoretical advantages. The delivery location, virus 
type, and promoter may allow for more selective manipulation of specific neuronal or 
glial populations. Viral vectors have been previously used to manipulate neurons prior to 
experimental TBI (Conte et al., 2008). In our case, because the transgene is required to 
exert local effects in the axonal compartment, we relied on the native axonal transport 
machinery. For proteins that are normally excluded from axons, selective subcellular 
targeting of expressed proteins to axons, which has been described by Stowell and 
Craig (1999), may be necessary. 
In the brain, it is often difficult to trace back large groups of axons of interest to 
specific neuronal populations as large white matter tracts often connect myriad and 
spatially diverse cell populations, thus limiting experimental manipulation and 
interpretation. This can be overcome in the optic nerve, which shares similar properties 
with white matter tracts within the brain, including poor regenerative capacity, myelin 
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sheath structure, and the presence of oligodendrocytes (Cho et al., 2005, Hirano and 
Lena, 1995). The axons are relatively homogenous in size, uni-directional and have well-
defined targets. Manipulating the parent neurons is technically straightforward and a 
large percentage of RGCs can be transduced after a single intravitreal injection (Martin 
and Quigley, 2004). In this report, we have demonstrated that transgene delivery to 
axons can be readily achieved in the optic nerve. As our injury model preferentially 
affects axons, this model in combination with our therapeutic AAV vector strategy 
allowed us to explore the mechanisms underlying axonal dysfunction after TBI. 
 
 
ZsGreen and hCAST accumulates in axonal swellings and bulbs 
In our study, we demonstrated that 4 days after optic nerve stretch, there were 
accumulations of 2 different exogenous proteins, ZsGreen and hCAST, which occurred 
at sites where axonal transport is presumably disrupted. Many of these swellings and 
bulbs labeled with the neurofilament marker SMI-32, classically used to detect swellings 
and bulbs (Ma et al., 2009; Saatman et al., 2003). If hCAST were completely protective 
after nerve stretch, we would not expect hCAST co-labeling with SMI-32 at axonal 
swellings. However, our optic nerve results are consistent with the incomplete protection 
seen in our main outcome measure, fluorogold labeling of RGCs. 
Examining optic nerves was useful as it allowed us to draw two conclusions. 
First, overexpression of ZsGreen or hCAST did not result in overt morphological injury of 
optic nerve axons. Second, stretched nerves in all rats were injured as they all had SMI-
32 immunoreactive swellings and bulbs, which were not seen in contralateral uninjured 
nerves. 
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Pathologic calpain activity contributes to retrograde transport disruption after 
optic nerve stretch 
Our main outcome measure was axonal function as opposed to classic 
histopathologic changes (axonal swellings and bulbs) as it has been proposed that a 
significant fraction of normal appearing axons may be rendered dysfunctional after 
trauma (Yuen et al., 2009). In this current study, unilateral optic nerve stretch disrupted 
fluorogold transport in 58.3±15.6% of ZsGreen+ RGCs, which is consistent with previous 
investigations (Ma et al., 2012; Saatman et al., 2003). After mouse optic nerve stretch, 
disruption of retrograde axonal transport occurs early and appears to be complete and 
permanent (Saatman et al., 2003). Stretch injury probably does not simply delay 
retrograde transport of fluorogold. 
Human CAST overexpression ameliorated retrograde transport disruption after 
stretch injury. The lack of complete protection by hCAST may be due to incomplete 
calpain inhibition, or the contribution of other injury mechanisms such as the microtubule 
destabilizing effects of elevated intraaxonal Ca2+ (Gaskin et al., 1975; Job et al., 1981; 
Keith et al., 1983; Maxwell et al., 1997) or other proteases. For example, caspase 
activity has been detected after experimental TAI (Büki and Povlishock, 2006; Büki et al., 
2000). 
A number of other studies have suggested that calpains play a role in TAI. Rats 
given an IV bolus of the calpain inhibitor MDL-28170 (30 mg/kg) 30 minutes prior to fluid 
percussion or impact head acceleration injury demonstrate reduced axonal swellings 
and bulbs and neurofilament compaction in brainstem fiber tracts (Büki et al., 2003), 
improved axolemmal integrity of the corticospinal tract (Czeiter et al., 2009), and 
structural and electrophysiological protection of the corpus callosum (Ai et al., 2007). 
Interpretation of these results requires caution though as MDL-28170 also inhibits 
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proteases other than calpains (Markgraf et al., 1998). As injury to supraaxonal structures 
and physiologic derangements after TBI may secondarily cause axonal dysfunction and 
degeneration, it is not clear if the protective effect of the calpain inhibitor occurs directly 
within axons. We attempted to address this question in an earlier investigation by using 
a model that primarily isolates mechanical strain to axons (Ma et al., 2012). Rats 
received a 30 mg/kg IV bolus of MDL-28170 30 minutes prior to unilateral optic nerve 
stretch. After the bolus, animals were infused the drug at 15 mg/kg/hr over the following 
2.5 hrs. Despite the early intensive therapy, which was designed to match the time 
course of early calpain activity (Saatman et al., 2003), we were unable to protect 
retrograde axonal transport measured 4 days after optic nerve stretch. It was not 
established if the duration of treatment or the intraaxonal concentration of MDL-28170 
was sufficient to block pathologic calpain activity.  
The mechanism by which calpains disrupt axonal transport has not been clearly 
established. The ultrastructural pathology seen after TAI is microtubule loss and 
neurofilament misalignment and compaction. Microtubule loss has been hypothesized to 
impair axonal transport (Maxwell, 1996; McCracken et al., 1999; Saatman et al., 2003). 
Maxwell and Graham (1997) demonstrated that 15 minutes after guinea pig optic nerve 
stretch, there was a dramatic loss of microtubules throughout axons. By 2 hours, 
internodal axonal swellings containing significantly reduced numbers of microtubules 
had developed. Calpains may directly proteolyze tubulin and tau (Billger et al., 1988; 
Johnson et al., 1989; Siman and Noszek, 1988), which is important for microtubule 
stability (Amos and Schlieper, 2005). It is not known if calpains contribute to microtubule 
loss in vivo as elevated Ca2+ has been shown to depolymerize microtubules directly or 
via activation of calmodulin (Gaskin et al., 1975; Job et al., 1981; Keith et al., 1983; 
    139 
O'Brien et al., 1997). Axonal stretch injury results in an acute rise in intraaxonal Ca2+ 
(Iwata et al., 2004; Ma et al., 2012; Staal et al., 2010). 
Neurofilament misalignment and compaction have been suggested to impair 
axonal transport (Christman et al., 1994; Smith and Meaney, 2000). Disruption of the 
ordered arrangement of neurofilaments occurs in human diffuse axonal injury (Christman 
et al., 1994). RMO14 is a commonly used marker of early axonal injury, presumably due 
to calpain proteolysis of sidearms on the neurofilament medium subunits (Büki et al., 
2003). RMO14 immunoreactivity is prominent in the corticospinal tract and medial 
longitudinal fasciculus in rodent head impact acceleration injury (Büki et al., 2003; Stone 
et al., 2001). In the corticospinal tract, RMO14 immunoreactive axons do not consistently 
stain with amyloid precursor protein (APP), which is a marker of swellings and bulbs, nor 
have evidence of organelle pooling, suggesting that neurofilament sidearm modifications 
may not directly impair axonal transport (Stone et al., 2001). The functional 
consequence of neurofilament sidearm modifications remains unclear.  
 
Limitations 
At baseline, a lower percentage of transduced RGCs labeled with fluorogold than 
was expected based on our preliminary unpublished data and work by others 
(Barnstable and Drager, 1984; Salinas-Navarro et al., 2009). Nevertheless, one blinded 
observer scored all retinas for fluorogold labeling. Because we did not attempt to 
formally answer whether viral transduction independently affected retrograde transport, 
speculating on why this may be so would be premature. There was a trend toward 
differential fluorogold labeling of uninjured ZsGreen and hCAST RGCs (69.4±9.6% 
versus 57.2±11.5%; p=0.02). Because of multiple comparisons p<0.013 was considered 
significant. As this discrepancy may have obscured a treatment effect if absolute 
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numbers were compared, we decided a priori to use the contralateral uninjured side in 
each animal as an internal control for baseline fluorogold labeling of transduced RGCs. 
The potential baseline difference in fluorogold labeling of ZsGreen+ and hCAST+ RGCs 
may be due to an intrinsic property of hCAST. Calpains may regulate key aspects of 
retrograde axonal transport. E-64 and leupeptin, which inhibit various proteases 
including calpains, prevent the anterograde-retrograde conversion of axonally 
transported vesicles (Sahenk and Lasek, 1988). Differential fluorogold labeling may also 
result from a more generalizable consequence of protein overexpression. For example, 
overexpressed proteins may require different molecular machinery for their own axonal 
transport, thereby “crowding out” other proteins that rely on the same transport 
mechanisms.  
Quantification of ZsGreen and hCAST swellings and bulbs was not performed for 
several reasons. First, the transduction efficiency of RGCs after intravitreal injection of 
AAV vectors was variable. Second, even assuming equal transduction efficiency of the 
two viral vectors, significantly more transduced axons in ZsGreen+ optic nerves than 
hCAST+ nerves would be detectable. It is easier to identify ZsGreen labeled axons as 
ZsGreen is intrinsically fluorescent and has high signal-to-noise. Third, their turnover 
rates and anterograde transport speeds are unknown, which may influence the formation 
and stability of swellings and bulbs identified using these two proteins. Given these 
caveats, no attempt was made to quantify swellings or bulbs.  
The variable and low transduction efficiency of the AAV vectors was a significant 
limitation when developing strategies to quantify the direct effects of the two 
overexpressed proteins on in vivo calpain activity after optic nerve stretch. Western blot 
for calpain-cleaved α-spectrin (Ab38) of optic nerve homogenates would not have been 
sensitive enough given the low transduction efficiency. In a previous study, we used 
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Ab38 immunohistochemistry to demonstrate increased intra-axonal calpain activity 30 
minutes after optic nerve stretch (Ma et al., 2012). However, it would have been 
challenging to quantify the amount of Ab38 labeling in transduced axons, whose 
diameters are approximately 1 µm, after optic nerve stretch. Given these limitations, we 
did not address whether hCAST at the levels present within axons could inhibit in vivo 
calpains using a more direct readout of calpain activity.  
 
Conclusions 
In summary, the present findings support our hypothesis that strain induced 
calpain activity within axons directly impairs retrograde transport. By using viral vector-
mediated transduction of RGCs and the native anterograde transport machinery, we 
were able to deliver the specific endogenous calpain inhibitor calpastatin to the site of 
greatest injury (the prechiasmatic optic nerve). This approach in our model of optic nerve 
stretch injury may help overcome the limitations of pharmacologic inhibitors and spur 
future studies exploring the molecular mechanisms of TAI.  
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Figure 5.1 
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Fig. 5.1. Expression of functional hCAST in primary cortical neuronal cultures. (A) AAV 
vectors expressing ZsGreen or hCAST were used to transduce primary cortical cultures 
(7 DIV). At 21 DIV, cultures were immunolabeled for hCAST (MAB3084) and stained for 
DAPI. Scale bar=20 µm. (B) In vitro analysis for calpastatin activity in cell extracts using 
a fluorogenic substrate assay. Calpain proteolysis of Suc-Leu-Tyr-MNA, which results in 
increasing fluorescence intensity, was almost completely blocked by hCAST 
overexpression. Values are mean±SD for 3-5 cortical neuronal cultures per group 
(*p<0.0001 versus nontransduced and ZsGreen expressing cells). Western blot 
confirmed hCAST only in cultures transduced with AAV.hCAST. 
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Figure 5.2 
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Fig. 5.2. Expression of ZsGreen or hCAST in RGCs and their axons within the optic 
nerve. (A) Rats were perfusion fixed 3 weeks after intravitreal injection of AAV.ZsGreen 
or AAV.hCAST. Representative images of retinal flat mounts immunolabeled with 
MAB3084 (hCAST) and/or an antibody directed against neuron-specific class III β-
tubulin that is used to label RGCs (PRB-435P). (B) Western blot of optic nerves 
confirmed hCAST overexpression only after intravitreal injection of AAV.hCAST. (C) 
Representative images of longitudinal sections of prechiasmatic optic nerves 
immunolabeled with MAB3084. Scale bar=20 µm. 
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Figure 5.3 
 
 
 
 
Fig. 5.3. Disruption of axonal transport after unilateral optic nerve stretch. Rats received 
bilateral intravitreal injections of AAV.ZsGreen or AAV.hCAST. After 3 weeks, unilateral optic 
nerve stretch, immediately followed by fluorogold injection, was performed. Animals were 
euthanized by perfusion fixation 4 days later. Longitudinal optic nerve sections were 
immunolabeled with SMI-32, which is commonly used to detect swellings and bulbs, and/or 
sc-20779 (CAST). Unilateral optic nerve stretch disrupted axonal transport, resulting in 
accumulations of ZsGreen and hCAST, which frequently label with SMI-32. Scale bar=10 
µm. 
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Figure 5.4 
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Fig. 5.4. Effect of hCAST on retrograde axonal transport disruption after optic nerve 
stretch. (A) Rats received bilateral intravitreal injections of AAV.ZsGreen or AAV.hCAST. 
After 3 weeks, unilateral optic nerve stretch, immediately followed by fluorogold injection, 
was performed. Animals were euthanized by perfusion fixation 4 days later. (A) 
Representative images of retinal flat mounts immunolabeled with an antibody directed 
against neuron-specific class III β-tubulin (PRB-435P), and/or MAB3084 (hCAST). 
Transduced RGCs labeled with fluorogold are marked with white circles, while those 
without fluorogold are marked with black circles. Scale bar=10 µm. (B) Quantification of 
RGCs (cells positive for neuron-specific class III β-tubulin) showed no apparent loss 4 
days after stretch injury. (C) Percentage of transduced RGCs that label with fluorogold. 
(D) Percent difference of fluorogold labeling of transduced RGCs between the injured 
and contralateral uninjured sides. Human CAST overexpression ameliorated the 
disruption of fluorogold transport after optic nerve stretch.  For (B), (C), and (D), each 
circle represents an individual retina, while horizontal bars represent means. *p<0.05 
**p≤0.001 
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CHAPTER 6: 
Discussion 
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The work described in the previous chapters extends our understanding of how 
calpains contribute to Wallerian degeneration and traumatic axonal injury (TAI). 
Specifically, in Chapter 2, we showed that transection of axons in vivo resulted in robust 
calpain activity on a time scale that is different in the CNS and PNS. Calpastatin 
overexpression provided biochemical protection in transected PNS and CNS axons. 
There was robust morphological protection in PNS axons, as well as structural 
preservation of NMJs. However, synaptic function was not preserved. Interestingly, 
previous investigators have described morphologically a type of degeneration in CNS 
axons that is not seen in the PNS (Marques et al., 2003; Narciso et al., 2001). The 
mechanistic basis of this difference is not known. Even though this was not formally 
addressed, our data suggests that calpains do not appear to contribute to “dark” 
degeneration. In Chapter 3, we developed and characterized the rat optic nerve stretch 
model that primarily isolates mechanical strains to axons. Immediate, short-duration mild 
hypothermia was axonal protective. The protective effect of hypothermia has been partly 
ascribed to calpain inhibition (Büki et al., 1999a). We proceeded to specifically address 
the role of calpains in TAI. In Chapter 4, pre-treatment with the pharmacologic calpain 
inhibitor MDL-28170 did not protect retrograde axonal transport. However, as detailed in 
Chapter 5, overexpression of CAST reduced retrograde axonal transport disruption by 
42%. These discordant results may be due to the short duration or lack of effective intra-
axonal drug concentration with intravenously delivered MDL-28170. Taken together, 
these findings provide compelling support that calpains directly contribute to cytoskeletal 
degeneration and axonal transport disruption in the diseased nervous system, and 
suggest that calpains are necessary but not sufficient to protect synaptic function. 
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Remaining questions and future directions 
 Our work raises important questions for future research into the role of calpains 
in axonal injury. In this dissertation, we relied on calpastatin overexpression to modulate 
calpain activity. Calpastatin inhibits both µ- and m-calpain, and it is not known whether 
other members of the calpain family are inhibited by calpastatin. As we have discussed, 
both µ- and m-calpain are likely present in axons, even though their relative amounts 
may be debated. As µ- and m-calpains serve different, but critical physiologic roles, 
selective targeting of the isoform or isoforms responsible for axonal injury may be 
necessary to minimize adverse effects. In our laboratory, we have used RNA 
interference to knock down m-calpain in primary hippocampal neurons, thereby 
protecting them from excitotoxic injury (Bevers et al., 2009). We can use these same 
tools in DRG cultures to answer the question of which isoform is responsible for the 
degeneration of transected neurites. The most straightforward way to address this 
question in vivo would be to use transgenic animals. There exists a µ-calpain knockout 
mouse that is viable and fertile, and its major abnormalities involve platelet function 
(Azam et al., 2001). Unfortunately, constitutive knockout of calpain 2 or the common 
small regulatory subunit, which is required for stability and activity of µ - and m-calpain, 
is embryonically lethal (Arthur et al., 2000; Dutt et al., 2006). Using conditional knockout 
mice may overcome this obstacle. 
 Previous studies have clearly established that the majority of degenerating CNS 
and PNS axons have different morphologies (Marques et al., 2003; Narciso et al., 2001). 
In our study, although calpastatin overexpression provided robust biochemical protection 
in both, it was unexpected that the morphological protection was much less apparent in 
CNS than in PNS axons. Based on the biochemical data, transected axons in transgenic 
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mice undergoing “dark” degeneration probably had preserved ultrastructure. The 
molecular mechanism and functional significance of “dark” degeneration are unknown.  
My dissertation has partly addressed the role of calpains in Wallerian 
degeneration and TAI. Transection of mammalian CNS and PNS axons results in 
irreversible degeneration of the distal segments. However, understanding the molecular 
mechanism or mechanisms underlying axonal degeneration is potentially critical for 
ameliorating many acute and chronic human diseases. In particular, there is a large 
group of toxic and genetic disorders in which degeneration is most prominent in distal 
parts of axons, known as “dying back” neuropathies (Coleman, 2005). In “dying back” 
neuropathies, degeneration starts distally on axons and spreads retrogradely. Our 
hCAST transgenic mouse is a powerful tool to address the role of calpains in these 
disorders. For example, our mice could be crossed with progressive motor neuropathy 
(pmn) mice or myelin protein zero (P0) null mutants – a model of Charcot-Marie-Tooth 
disease.  
Our hCAST transgenic mice could also be used more broadly, by addressing the 
role of calpains in neurodegenerative disorders, for example. It has become clear that 
most, and possibly all, neurodegenerative diseases involve major synapse and axon 
loss prior to the appearance of symptoms, and long before neuronal loss is evident 
(Saxena and Caroni, 2007). These diseases include Alzheimer’s, Parkinson’s, 
Huntington’s, motor neuron disease, and prion diseases, and there is evidence that 
calpains may play a role in their pathogenesis (Bizat et al., 2005; Crocker et al., 2003; 
Kieran and Greensmith, 2004; Li et al., 1998; Trancikova et al., 2011; Trinchese et al., 
2008; Yadavalli et al., 2004). There are transgenic mouse models for many 
neurodegenerative disorders (see review by Trancikova et al., 2011). 
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Interaction of calpains with other axon degeneration pathways 
It was once believed that transected axons, deprived of nutrients from the 
somata, passively wasted away. However, with the identification and characterization of 
the Wlds mutation, that is no longer considered true. Axon degeneration is an active, 
tightly controlled process, and from that perspective, similar to apoptosis. However, 
there is strong evidence that the apoptotic machinery is not important in Wallerian 
degeneration (Finn et al., 2000; Kilinc et al., 2010; Schoenmann et al., 2010; Whitmore 
et al., 2003). There are two other non-calpain mechanisms that may contribute to axonal 
degeneration: the ubiquitin-proteasome system (UPS) and autophagy (Knöferle et al., 
2010; Zhai et al., 2003;). Much less is known about the role of autophagy in axonal 
degeneration. To end this dissertation, I will briefly discuss UPS and a potential 
convergence between calpains and the UPS. 
The notion that UPS may be important in WD came from the identification of the 
Wlds gene, which is formed by a stable triplication encoding the N-terminus of 
multiubiquitylation factor Ube4b fused in-frame to the Nmnat1. In the UPS, ubiquitin is 
conjugated to proteins to signal their degradation by the proteasome, an abundant ATP-
dependent protease. Inhibition of UPS, but not calpains, protects the axolemma and 
microtubule structure of transected neurites (Zhai et al., 2003). Inhibiting either UPS or 
calpains protects neurofilaments however. These results suggest that the UPS and 
calpains may act on different aspects of Wallerian degeneration. Axonal protection with 
UPS inhibition by pharmacologic and genetic means was confirmed in vivo (Hoopfer et 
al., 2006; Wakatsuki et al., 2011; Zhai et al., 2003). Wakatsuki and colleagues (2011) 
described an elegant pathway linking ZNRF1 ubiquitin ligase to axonal degeneration. 
Through a series of intermediaries, activation of ZNRF1 results in the phosphorylation at 
the 514th threonine residue of collapsing response mediator protein-2 (CRMP2), 
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abolishing its stabilizing activity on microtubules. Interestingly, calpains are known to 
cleave CRMP2 at its C-terminus (Touma et al., 2007; Zhang et al., 2007). Proteolysis is 
not predicted to affect its binding to microtubules, but may alter tubulin transport. Even 
though the cleavage site is not known, it is likely near to the 514th amino acid. The 
interplay between proteolysis and phosphorylation of CRMP2 in Wallerian degeneration 
may be worthy of study. 
 
Final Conclusions 
In summary, I show that calpains play a causal role in key aspects of axonal 
dysfunction and degeneration in several different injury models. Additionally, the tools 
and models employed or developed in the course of this research may have an impact 
on elucidating molecular mechanisms underlying diverse human diseases. The hCAST 
transgenic mouse is a powerful tool to study the role of calpains in a wide spectrum of 
disorders. In addition, studying the interplay of calpains with other axon degeneration 
pathways may yield important insights.  
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